<root><template><title>Other uses</title></template>
<template lineStart="1"><title>Use dmy dates</title><part><name>date</name><equals>=</equals><value>February 2014</value></part></template>
<template lineStart="1"><title>Sprotect</title><part><name>small</name><equals>=</equals><value>yes</value></part></template><template><title>pp-move-indef</title></template>
<template lineStart="1"><title>Infobox disease
</title><part><name> Name </name><equals>=</equals><value> Schizophrenia
</value></part><part><name> Image </name><equals>=</equals><value> Cloth embroidered by a schizophrenia sufferer.jpg
</value></part><part><name> Caption </name><equals>=</equals><value> Cloth embroidered by a person diagnosed with schizophrenia
</value></part><part><name> Width </name><equals>=</equals><value>
</value></part><part><name> DiseasesDB </name><equals>=</equals><value> 11890
</value></part><part><name> ICD10 </name><equals>=</equals><value> <template><title>ICD10</title><part><name index="1"/><value>F</value></part><part><name index="2"/><value>20</value></part><part><name index="3"/><value/></part><part><name index="4"/><value>f</value></part><part><name index="5"/><value>20</value></part></template>
</value></part><part><name> ICD9 </name><equals>=</equals><value> <template><title>ICD9</title><part><name index="1"/><value>295</value></part></template>
</value></part><part><name> ICDO </name><equals>=</equals><value>
</value></part><part><name> OMIM </name><equals>=</equals><value> 181500
</value></part><part><name> MedlinePlus </name><equals>=</equals><value> 000928
</value></part><part><name> eMedicineSubj </name><equals>=</equals><value> med
</value></part><part><name> eMedicineTopic </name><equals>=</equals><value> 2072
</value></part><part><name> eMedicine_mult </name><equals>=</equals><value> <template><title>eMedicine2</title><part><name index="1"/><value>emerg</value></part><part><name index="2"/><value>520</value></part></template>
</value></part><part><name> MeshName </name><equals>=</equals><value> Schizophrenia
</value></part><part><name> MeshNumber </name><equals>=</equals><value> F03.700.750 </value></part><part><name index="1"/><value/></part></template>
<comment>&lt;!--Para1: Definition, symptoms and diagnosis--&gt;
</comment>'''Schizophrenia''' (<template><title>IPAc-en</title><part><name index="1"/><value>ˌ</value></part><part><name index="2"/><value>s</value></part><part><name index="3"/><value>k</value></part><part><name index="4"/><value>ɪ</value></part><part><name index="5"/><value>t</value></part><part><name index="6"/><value>s</value></part><part><name index="7"/><value>ɵ</value></part><part><name index="8"/><value>ˈ</value></part><part><name index="9"/><value>f</value></part><part><name index="10"/><value>r</value></part><part><name index="11"/><value>ɛ</value></part><part><name index="12"/><value>n</value></part><part><name index="13"/><value>i</value></part><part><name index="14"/><value>ə</value></part></template> or <template><title>IPAc-en</title><part><name index="1"/><value>ˌ</value></part><part><name index="2"/><value>s</value></part><part><name index="3"/><value>k</value></part><part><name index="4"/><value>ɪ</value></part><part><name index="5"/><value>t</value></part><part><name index="6"/><value>s</value></part><part><name index="7"/><value>ɵ</value></part><part><name index="8"/><value>ˈ</value></part><part><name index="9"/><value>f</value></part><part><name index="10"/><value>r</value></part><part><name index="11"/><value>iː</value></part><part><name index="12"/><value>n</value></part><part><name index="13"/><value>i</value></part><part><name index="14"/><value>ə</value></part></template>) is a [[mental disorder]] often characterized by abnormal social behavior and failure to recognize what is [[reality|real]]. Common symptoms include [[Delusion|false beliefs]], [[thought disorder|unclear or confused thinking]], [[auditory hallucination]]s, reduced social engagement and emotional expression, and [[Avolition|inactivity]]. Diagnosis is based on observed behavior and the person's reported experiences.

<comment>&lt;!--Para2:Cause--&gt;
</comment>[[Genetics]] and early environment, as well as [[Psychology|psychological]] and social processes, appear to be important contributory factors. Some recreational and prescription drugs appear to cause or worsen symptoms. The many possible combinations of symptoms have triggered debate about whether the diagnosis represents a single disorder or a number of separate syndromes. Despite the [[etymology|origin]] of the term from the [[Ancient Greek|Greek]] roots ''skhizein'' (&quot;to split&quot;) and ''phrēn'' (&quot;mind&quot;), schizophrenia does not imply a &quot;split personality&quot;, or &quot;[[dissociative identity disorder|multiple personality disorder]]&quot;—a condition with which it is often confused in public perception.<ext><name>ref</name><attr> name=BMJ07</attr></ext> Rather, the term means a &quot;splitting of mental functions&quot;, reflecting the presentation of the illness.<ext><name>ref</name><attr/><inner>{{cite book |author= Baucum, Don |title= Psychology |year= 2006 |publisher= Barron's |location=Hauppauge, N.Y. |isbn=9780764134210|page=182|url=http://books.google.ca/books?id=iCVSdYdA36EC&amp;pg=PA182|edition=2nd}}</inner><close>&lt;/ref&gt;</close></ext>

<comment>&lt;!--Para3: Treatment--&gt;
</comment>The mainstay of treatment is [[antipsychotic]] medication, which primarily suppresses [[dopamine]] [[Receptor (biochemistry)|receptor]] activity. [[Psychotherapy|Counseling]], job training and social rehabilitation are also important in treatment. In more serious cases—where there is risk to self or others—[[emergency psychiatry|involuntary hospitalization]] may be necessary, although hospital stays are now shorter and less frequent than they once were.<ext><name>ref</name><attr> name=&quot;BeckerKilian2006&quot;</attr><inner>{{cite journal |author=Becker T, Kilian R|year=2006 |title=Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care? |journal=[[Acta Psychiatrica Scandinavica]] Supplement |volume=113 |pages=9–16 |pmid=16445476 |doi=10.1111/j.1600-0447.2005.00711.x |issue=429}}</inner><close>&lt;/ref&gt;</close></ext>

<comment>&lt;!--Para4: Epidemiology and prognosis--&gt;
</comment>Symptoms begin typically in young adulthood, and about 0.3–0.7% of people are affected during their lifetime.<ext><name>ref</name><attr> name=Lancet09</attr></ext> The disorder is thought to mainly affect the ability to [[cognition|think]], but it also usually contributes to chronic problems with behavior and emotion. People with schizophrenia are likely to have additional conditions, including [[Major depressive disorder|major depression]] and [[anxiety disorder]]s; the lifetime occurrence of [[substance use disorder]] is almost 50%.<ext><name>ref</name><attr> name=&quot;Sim_et_al_2006&quot;</attr><inner>{{cite journal |author=Buckley PF, Miller BJ, Lehrer DS, Castle DJ |title=Psychiatric comorbidities and schizophrenia |journal=Schizophr Bull |volume=35 |issue=2 |pages=383–402 |date=March 2009  |pmid=19011234 |pmc=2659306 |doi=10.1093/schbul/sbn135}}</inner><close>&lt;/ref&gt;</close></ext> Social problems, such as long-term unemployment, poverty, and homelessness are common. The average [[life expectancy]] of people with the disorder is ten to twenty five years less than the average life expectancy.<ext><name>ref</name><attr> name=Lauren2012</attr></ext> This is the result of increased physical health problems and a higher [[suicide]] rate (about 5%).<ext><name>ref</name><attr> name=Lancet09</attr></ext><ext><name>ref</name><attr> name=Jop2010</attr><inner>{{cite journal|author=Hor K, Taylor M|title=Suicide and schizophrenia: a systematic review of rates and risk factors |journal=Journal of psychopharmacology (Oxford, England)|date=November 2010|volume=24|issue=4 Suppl|pages=81–90|pmid=20923923|doi=10.1177/1359786810385490}}</inner><close>&lt;/ref&gt;</close></ext>
<template lineStart="1"><title>TOC limit</title><part><name index="1"/><value>3</value></part></template>

<h level="2" i="1">==Symptoms==</h>
[[File:Artistic view of how the world feels like with schizophrenia - journal.pmed.0020146.g001.jpg|thumb|right|[[Self-portrait]] of a person with schizophrenia, representing that individual's perception of the distorted experience of reality in the disorder]]

Individuals with schizophrenia may experience [[hallucination]]s (most reported are [[Auditory hallucination|hearing voices]]), [[delusion]]s (often bizarre or [[Persecutory delusions|persecutory]] in nature), and [[Thought disorder|disorganized thinking and speech]]. The last may range from loss of train of thought, to sentences only loosely connected in meaning, to speech that is not understandable known as [[Schizophasia|word salad]] in severe cases. Social withdrawal, sloppiness of dress and hygiene, and loss of motivation and judgment are all common in schizophrenia.<ext><name>ref</name><attr> name=CarsonNursing</attr><inner>Carson VB (2000). [http://books.google.com/books?id=QM5rAAAAMAAJ Mental health nursing: the nurse-patient journey] W.B. Saunders. ISBN 978-0-7216-8053-8. p. 638.</inner><close>&lt;/ref&gt;</close></ext> There is often an observable pattern of emotional difficulty, for example lack of responsiveness.<ext><name>ref</name><attr> name=&quot;HirschWeinberger2003p21&quot;</attr><inner>{{cite book|author1=Hirsch SR|author2= Weinberger DR|title=Schizophrenia|url=http://books.google.com/books?id=x3fmsV55rigC&amp;pg=PA21|year= 2003|publisher=Wiley-Blackwell|isbn=978-0-632-06388-8|page=21}}</inner><close>&lt;/ref&gt;</close></ext> Impairment in [[social cognition]] is associated with schizophrenia,<ext><name>ref</name><attr/><inner>{{cite journal |author=Brunet-Gouet E, Decety J |title=Social brain dysfunctions in schizophrenia: a review of neuroimaging studies |journal=Psychiatry Res |volume=148 |issue=2–3 |pages=75–92 |date=December 2006  |pmid=17088049 |doi=10.1016/j.pscychresns.2006.05.001}}</inner><close>&lt;/ref&gt;</close></ext> as are symptoms of [[paranoia]]. [[Social isolation]] commonly occurs.<ext><name>ref</name><attr> name=&quot;HirschWeinberger2003p481&quot;</attr><inner>{{cite book|author1=Hirsch SR|author2= WeinbergerDR|title=Schizophrenia|url=http://books.google.com/books?id=x3fmsV55rigC&amp;pg=PA21|year= 2003|publisher=Wiley-Blackwell|isbn=978-0-632-06388-8|page=481}}</inner><close>&lt;/ref&gt;</close></ext> Difficulties in [[Working memory|working]] and [[long-term memory]], [[attention]], [[Executive functions|executive functioning]], and speed of [[Information processing|processing]] also commonly occur.<ext><name>ref</name><attr> name=Lancet09</attr></ext> In one uncommon subtype, the person may be largely mute, remain motionless in bizarre postures, or exhibit purposeless agitation, all signs of [[catatonia]].<ext><name>ref</name><attr/><inner>{{cite journal |author=Ungvari GS, Caroff SN, Gerevich J |title=The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders |journal=Schizophr Bull |volume=36 |issue=2 |pages=231–8 |date=March 2010  |pmid=19776208 |doi=10.1093/schbul/sbp105 |pmc=2833122}}</inner><close>&lt;/ref&gt;</close></ext> About 30 to 50% of people with schizophrenia fail to accept that they have an illness or their recommended treatment.<ext><name>ref</name><attr/><inner>{{cite journal|author=Baier M|title=Insight in schizophrenia: a review|journal=Current psychiatry reports|date=August 2010|volume=12|issue=4|pages=356–61|pmid=20526897|doi=10.1007/s11920-010-0125-7}}</inner><close>&lt;/ref&gt;</close></ext> Treatment may have some effect on insight.<ext><name>ref</name><attr/><inner>{{cite journal|author=Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A|title=Changes in insight during treatment for psychotic disorders: a meta-analysis|journal=Schizophrenia research|date=March 2013|volume=144|issue=1–3|pages=109–17|pmid=23305612|doi=10.1016/j.schres.2012.11.018}}</inner><close>&lt;/ref&gt;</close></ext> People with schizophrenia often find facial emotion perception to be difficult.<ext><name>ref</name><attr/><inner>{{cite journal |author=Kohler CG, Walker JB, Martin EA, Healey KM, Moberg PJ |title=Facial emotion perception in schizophrenia: a meta-analytic review |journal=Schizophr Bull |volume=36 |issue=5 |pages=1009–19 |date=September 2010  |pmid=19329561 |pmc=2930336 |doi=10.1093/schbul/sbn192 |url=http://schizophreniabulletin.oxfordjournals.org/content/36/5/1009.full}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="2">===Positive and negative===</h>
Schizophrenia is often described in terms of [[Symptom#Positive and negative|positive and negative (or deficit) symptoms]].<ext><name>ref</name><attr> name=&quot;Sims_2002&quot;</attr><inner>{{cite book |author=Sims A |title=Symptoms in the mind: an introduction to descriptive psychopathology |publisher=W. B. Saunders |location=Philadelphia |year=2002 |isbn=0-7020-2627-1 }}</inner><close>&lt;/ref&gt;</close></ext> Positive symptoms are those that most individuals do not normally experience but are present in people with schizophrenia. They can include delusions, disordered thoughts and speech, and [[tactile]], [[Auditory hallucination|auditory]], [[visual]], [[olfactory]] and [[gustatory]] hallucinations, typically regarded as manifestations of [[psychosis]].<ext><name>ref</name><attr/><inner>Kneisl C. and Trigoboff E. (2009). Contemporary Psychiatric- Mental Health Nursing. 2nd edition. London: Pearson Prentice Ltd. p. 371</inner><close>&lt;/ref&gt;</close></ext> Hallucinations are also typically related to the content of the delusional theme.<ext><name>ref</name><attr> name=DSM299</attr></ext> Positive symptoms generally respond well to medication.<ext><name>ref</name><attr> name=DSM299</attr><inner>American Psychiatric Association. Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Pub. ISBN 978-0-89042-025-6. p. 299</inner><close>&lt;/ref&gt;</close></ext>

Negative symptoms are deficits of normal emotional responses or of other thought processes, and respond less well to medication.<ext><name>ref</name><attr> name=CarsonNursing</attr></ext> They commonly include flat expressions or [[blunted affect|little emotion]], [[alogia|poverty of speech]], [[anhedonia|inability to experience pleasure]], [[asociality|lack of desire to form relationships]], and [[avolition|lack of motivation]]. Negative symptoms appear to contribute more to poor quality of life, functional ability, and the burden on others than do positive symptoms.<ext><name>ref</name><attr/><inner>{{cite journal |author=Velligan DI and Alphs LD|title=Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment |journal=Psychiatric Times |volume=25 |issue=3 |date=1 March 2008 |url=http://www.psychiatrictimes.com/schizophrenia/article/10168/1147581}}</inner><close>&lt;/ref&gt;</close></ext> People with greater negative symptoms often have a history of poor adjustment before the onset of illness, and response to medication is often limited.<ext><name>ref</name><attr> name=CarsonNursing</attr></ext><ext><name>ref</name><attr> name=AFP10</attr></ext>

<h level="3" i="3">===Onset===</h>
Late adolescence and early adulthood are peak periods for the onset of schizophrenia,<ext><name>ref</name><attr> name=Lancet09</attr><inner>{{cite journal |author=[[Jim van Os|van Os J]], Kapur S |title=Schizophrenia |journal=Lancet |volume=374 |issue=9690 |pages=635–45 |date=August 2009  |pmid=19700006 |doi=10.1016/S0140-6736(09)60995-8|url= http://xa.yimg.com/kq/groups/19525360/611943554/name/Schizophrenia+-+The+Lancet.pdf }}</inner><close>&lt;/ref&gt;</close></ext> critical years in a young adult's social and vocational development.<ext><name>ref</name><attr> name=&quot;Addington_et_al_2007&quot;</attr></ext> In 40% of men and 23% of women diagnosed with schizophrenia, the condition manifested itself before the age of 19.<ext><name>ref</name><attr> name=Cullen</attr><inner>{{cite journal |author=Cullen KR, Kumra S, Regan J et al. |title=Atypical Antipsychotics for Treatment of Schizophrenia Spectrum Disorders |journal=Psychiatric Times |volume=25 |issue=3 |year=2008 |url=http://www.psychiatrictimes.com/schizophrenia/article/10168/1147536}}</inner><close>&lt;/ref&gt;</close></ext> To minimize the developmental disruption associated with schizophrenia, much work has recently been done to identify and treat the [[prodrome|prodromal (pre-onset)]] phase of the illness, which has been detected up to 30&amp;nbsp;months before the onset of symptoms.<ext><name>ref</name><attr> name=&quot;Addington_et_al_2007&quot;</attr><inner>{{cite journal |author=Addington J, Cadenhead KS, Cannon TD, et al.|year=2007|title=North American prodrome longitudinal study: a collaborative multisite approach to prodromal schizophrenia research |journal=[[Schizophrenia Bulletin]] |volume=33 | issue=3 |pages=665–72 |pmid=17255119|doi=10.1093/schbul/sbl075 |pmc=2526151}}</inner><close>&lt;/ref&gt;</close></ext> Those who go on to develop schizophrenia may experience transient or self-limiting psychotic symptoms<ext><name>ref</name><attr> name=&quot;Amminger_et_al_2006&quot;</attr><inner>{{cite journal |author=Amminger GP, Leicester S, Yung AR, et al. |year=2006 |title=Early onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals |journal=[[Schizophrenia Research]] |volume=84 | issue=1 |pages=67–76 |pmid=16677803 |doi=10.1016/j.schres.2006.02.018}}</inner><close>&lt;/ref&gt;</close></ext> and the non-specific symptoms of social withdrawal, irritability, [[dysphoria]],<ext><name>ref</name><attr> name=&quot;ParnasJorgensen1989&quot;</attr><inner>{{cite journal |author=Parnas J, Jorgensen A |year=1989 |title=Pre-morbid psychopathology in schizophrenia spectrum |journal=[[British Journal of Psychiatry]] |volume=115 |pages=623–7 |pmid=2611591}}</inner><close>&lt;/ref&gt;</close></ext> and clumsiness<ext><name>ref</name><attr> name=Coyle</attr><inner>{{cite book  |author=Coyle, Joseph |editor= Siegal, George J et al. |title=Basic Neurochemistry: Molecular, Cellular and Medical Aspects |edition=7th |year=2006 |publisher=Elsevier Academic Press |location=Burlington, MA |isbn=0-12-088397-X |pages=876–78 |chapter=Chapter 54: The Neurochemistry of Schizophrenia}}</inner><close>&lt;/ref&gt;</close></ext> during the prodromal phase.

<h level="2" i="4">==Causes==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Causes of schizophrenia</value></part></template>

A combination of genetic and [[environmental factor]]s play a role in the development of schizophrenia.<ext><name>ref</name><attr> name=BMJ07</attr></ext><ext><name>ref</name><attr> name=Lancet09</attr></ext> People with a family history of schizophrenia who have a transient psychosis have a 20–40% chance of being diagnosed one year later.<ext><name>ref</name><attr> name=&quot;Drake_Lewis_2005&quot;</attr><inner>{{cite journal |author=Drake RJ, Lewis SW |title=Early detection of schizophrenia |journal=Current Opinion in Psychiatry |volume=18 |issue=2 |pages=147–50 |date=March 2005  |pmid=16639167 |doi=10.1097/00001504-200503000-00007}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="5">===Genetic===</h>
Estimates of [[heritability]] vary because of the difficulty in separating the effects of genetics and the environment;<ext><name>ref</name><attr> name=&quot;ODonovan_et_al_2003&quot;</attr><inner>{{cite journal |author=O'Donovan MC, Williams NM, Owen MJ |title=Recent advances in the genetics of schizophrenia |journal=Hum. Mol. Genet. |volume=12 Spec No 2 |pages=R125–33 |date=October 2003  |pmid=12952866 |doi=10.1093/hmg/ddg302}}</inner><close>&lt;/ref&gt;</close></ext> averages of 0.80 have been given.<ext><name>ref</name><attr> name=Her2011</attr></ext> The greatest risk for developing schizophrenia is having a [[first-degree relative]] with the disease (risk is 6.5%); more than 40% of [[monozygotic twins]] of those with schizophrenia are also affected.<ext><name>ref</name><attr> name=BMJ07</attr></ext> If one parent is affected the risk is about 13% and if both are affected the risk is nearly 50%.<ext><name>ref</name><attr> name=Her2011</attr><inner>{{cite book|author=Herson M|title=Adult psychopathology and diagnosis |year=2011 |publisher=John Wiley &amp; Sons |isbn=9781118138847 |url=http://books.google.ca/books?id=iJtzm1KfU5oC&amp;pg=PT282 |chapter= Etiological considerations}}</inner><close>&lt;/ref&gt;</close></ext>

It is likely that many [[genes]] are involved, each of small effect and unknown transmission and expression.<ext><name>ref</name><attr> name=BMJ07</attr></ext> Many possible candidates have been proposed, including specific [[Copy-number variation|copy number variations]], [[NOTCH4]], and histone protein loci.<ext><name>ref</name><attr> name=Genes10</attr><inner>{{cite journal |author=McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W |title=Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies |journal=Int. J. Drug Policy |volume=21 |issue=1 |pages=10–9 |date=January 2010  |pmid=19783132 |doi=10.1016/j.drugpo.2009.09.001 |url=}}</inner><close>&lt;/ref&gt;</close></ext> A number of [[Genome-wide association study|genome-wide associations]] such as [[zinc finger protein 804A]] have also been linked.<ext><name>ref</name><attr/><inner>{{cite journal |author=O'Donovan MC, Craddock NJ, Owen MJ |title=Genetics of psychosis; insights from views across the genome |journal=Hum. Genet. |volume=126 |issue=1 |pages=3–12 |date=July 2009  |pmid=19521722 |doi=10.1007/s00439-009-0703-0}}</inner><close>&lt;/ref&gt;</close></ext> There appears to be overlap in the genetics of schizophrenia and [[bipolar disorder]].<ext><name>ref</name><attr/><inner>{{cite journal | author = Craddock N, Owen MJ | title = The Kraepelinian dichotomy - going, going... But still not gone | journal = The British Journal of Psychiatry | volume = 196 | pages = 92–95| year = 2010 | doi = 10.1192/bjp.bp.109.073429 | pmid=20118450 | pmc=2815936}}</inner><close>&lt;/ref&gt;</close></ext> Evidence is emerging that the genetic architecture of schizophrenia involved both common and rare risk variation.<ext><name>ref</name><attr/><inner>{{cite journal | author = Moore S, Kelleher E, Corvin A. | title = The shock of the new: progress in schizophrenia genomics | journal = Current Genomics  | volume = 12 |issue= 7 | pages = 516–24 | year = 2011 | doi = 10.2174/138920211797904089 | pmid=22547958 |pmc= 3219846 }}</inner><close>&lt;/ref&gt;</close></ext>

Assuming a hereditary basis, one question from [[evolutionary psychology]] is why genes that increase the likelihood of psychosis evolved, assuming the condition would have been [[maladaptive]] from an evolutionary point of view. One idea is that genes are involved in the evolution of language and [[human nature]], but to date such ideas remain little more than hypothetical in nature.<ext><name>ref</name><attr> name=&quot;pmid18502103&quot;</attr><inner>{{cite journal |author=Crow TJ |title=The 'big bang' theory of the origin of psychosis and the faculty of language |journal=[[Schizophrenia Research]] |volume=102 |issue=1–3 |pages=31–52 |date=July 2008  |pmid=18502103 |doi=10.1016/j.schres.2008.03.010 }}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite book|title=Clinical Handbook of Schizophrenia|year=2008|isbn=1-59385-652-0|pages=22–23|author=Mueser KT, Jeste DV|publisher=Guilford Press|location=New York}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="6">===Environment===</h>
Environmental factors associated with the development of schizophrenia include the living environment, drug use and prenatal stressors.<ext><name>ref</name><attr> name=Lancet09</attr></ext> Parenting style seems to have no major effect, although people with supportive parents do better than those with critical or hostile parents.<ext><name>ref</name><attr> name=BMJ07</attr></ext> Childhood trauma, separation from ones families, and being bullied or abused increase the risk of psychosis.<ext><name>ref</name><attr/><inner>{{cite web|title=THE ABANDONED ILLNESS|url=http://www.rethink.org/media/514093/TSC_main_report_14_nov.pdf|work=Schizophrenia Commission|accessdate=19 April 2014|page=10|date=Nov 2012}}</inner><close>&lt;/ref&gt;</close></ext> Living in an urban environment during childhood or as an adult has consistently been found to increase the risk of schizophrenia by a factor of two,<ext><name>ref</name><attr> name=BMJ07</attr></ext><ext><name>ref</name><attr> name=Lancet09</attr></ext> even after taking into account [[Recreational drug use|drug use]], [[ethnic group]], and size of [[social group]].<ext><name>ref</name><attr> name=&quot;fn_19&quot;</attr><inner>{{cite journal |author=[[Jim van Os|Van Os J]] |year=2004 |title=Does the urban environment cause psychosis? |journal=[[British Journal of Psychiatry]] |volume=184 | issue=4 |pages=287–288 |pmid=15056569 |doi=10.1192/bjp.184.4.287}}</inner><close>&lt;/ref&gt;</close></ext> Other factors that play an important role include [[social isolation]] and immigration related to social adversity, racial discrimination, family dysfunction, unemployment, and poor housing conditions.<ext><name>ref</name><attr> name=BMJ07</attr></ext><ext><name>ref</name><attr> name=&quot;Selten_et_al_2007&quot;</attr><inner>{{cite journal |author=Selten JP, Cantor-Graae E, Kahn RS |date=March 2007  |title=Migration and schizophrenia |journal=Current Opinion in Psychiatry |volume=20 |issue=2 |pages=111–115 |pmid=17278906 |doi=10.1097/YCO.0b013e328017f68e}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="4" i="7">====Substance use====</h>
About half of those with schizophrenia use drugs or alcohol excessively.<ext><name>ref</name><attr> name=Gregg2007</attr></ext>
Amphetamine, cocaine, and to a lesser extent alcohol, can result in psychosis that presents very similarly to schizophrenia.<ext><name>ref</name><attr> name=BMJ07</attr></ext><ext><name>ref</name><attr> name=alcohol</attr><inner>{{cite web|url=http://www.emedicine.com/med/topic3113.htm |title=Alcohol-Related Psychosis |accessdate=27 September 2006 |author=Larson, Michael |date=30 March 2006 |work=eMedicine |publisher=WebMD}}</inner><close>&lt;/ref&gt;</close></ext>  Although it is not generally believed to be a cause of the illness, people with schizophrenia use [[nicotine]] at much greater rates than the general population.<ext><name>ref</name><attr/><inner>{{cite journal |author=Sagud M, Mihaljević-Peles A, Mück-Seler D, et al. |title=Smoking and schizophrenia |journal=Psychiatr Danub |volume=21 |issue=3 |pages=371–5 |date=September 2009  |pmid=19794359 |url= http://www.hdbp.org/psychiatria_danubina/pdf/dnb_vol21_no3/dnb_vol21_no3_371.pdf}}</inner><close>&lt;/ref&gt;</close></ext>

[[Alcohol abuse]] can occasionally cause the development of a chronic substance-induced psychotic disorder via a [[kindling (sedative-hypnotic withdrawal)|kindling mechanism]].<ext><name>ref</name><attr> name=emedicine</attr><inner>{{EMedicine|med|3113|Alcohol-Related Psychosis}}</inner><close>&lt;/ref&gt;</close></ext> Alcohol use is not associated with an earlier onset of psychosis.<ext><name>ref</name><attr> name=Large2011</attr><inner>{{cite journal |author=Large M, Sharma S, Compton MT, Slade T, Nielssen O |title=Cannabis use and earlier onset of psychosis: a systematic meta-analysis |journal=Arch. Gen. Psychiatry |volume=68 |issue=6 |pages=555–61 |date=June 2011  |pmid=21300939 |doi=10.1001/archgenpsychiatry.2011.5}}</inner><close>&lt;/ref&gt;</close></ext>

A significant proportion of people with schizophrenia use [[Cannabis (drug)|cannabis]] to help cope with its symptoms.<ext><name>ref</name><attr> name=Gregg2007</attr></ext>  Cannabis can be a contributory factor in schizophrenia,<ext><name>ref</name><attr> name=Chadwick2013</attr><inner>{{cite journal |author=Chadwick B, Miller ML, Hurd YL |title=Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness |journal=Front Psychiatry |volume=4 |issue= |pages=129 |year=2013 |pmid=24133461 |pmc=3796318 |doi=10.3389/fpsyt.2013.00129|type=Review}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=Niesink2013</attr><inner>{{cite journal |author=Niesink RJ, van Laar MW |title=Does cannabidiol protect against adverse psychological effects of THC? |journal=Frontiers in Psychiatry |volume=4 |pages=130 |year=2013 |pmid=24137134 |pmc=3797438 |doi=10.3389/fpsyt.2013.00130|type=Review }}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=Parakh2013</attr><inner>{{cite journal |author=Parakh P, Basu D |title=Cannabis and psychosis: have we found the missing links? |journal=Asian Journal of Psychiatry |volume=6 |issue=4 |pages=281–7 |date= August 2013 |pmid=23810133 |doi=10.1016/j.ajp.2013.03.012|type=Review| quote=Cannabis acts as a component cause of psychosis, that is, it increases the risk of psychosis in people with certain genetic or environmental vulnerabilities, though by itself, it is neither a sufficient nor a necessary cause of psychosis.}}</inner><close>&lt;/ref&gt;</close></ext> but cannot cause it alone;<ext><name>ref</name><attr> name=Parakh2013</attr></ext> its use is neither necessary nor sufficient for development of any form of psychosis.<ext><name>ref</name><attr> name=Parakh2013</attr></ext> Early exposure of the developing brain to cannabis increases the risk of schizophrenia,<ext><name>ref</name><attr> name=Chadwick2013</attr></ext> although the size of the increased risk is difficult to quantify;<ext><name>ref</name><attr> name=Chadwick2013</attr></ext><ext><name>ref</name><attr> name=Niesink2013</attr></ext> only a small proportion of early cannabis recreational users go on to develop any schizoaffective disorder in adult life,<ext><name>ref</name><attr> name=Niesink2013</attr></ext> and the increased risk may require the presence of certain genes within an individual<ext><name>ref</name><attr> name=Parakh2013</attr></ext> or may be related to preexisting psychopathology.<ext><name>ref</name><attr> name= Chadwick2013</attr></ext> Higher dosage and greater frequency of use are indicators of increased risk of chronic psychoses.<ext><name>ref</name><attr> name=Niesink2013</attr></ext> [[Tetrahydrocannabinol]] (THC) and [[cannabidiol]] (CBD) produce opposing effects; CBD has antipsychotic and neuroprotective properties and counteracts negative effects of THC.<ext><name>ref</name><attr> name=Niesink2013</attr></ext>

Other drugs may be used only as coping mechanisms by individuals who have schizophrenia to deal with depression, anxiety, boredom, and loneliness.<ext><name>ref</name><attr> name=Gregg2007</attr><inner>{{cite journal |author=Gregg L, Barrowclough C, Haddock G |year=2007 |title= Reasons for increased substance use in psychosis |journal= Clin Psychol Rev |volume=27 |issue=4 |pages=494–510 |pmid=17240501 |doi=10.1016/j.cpr.2006.09.004}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=Leweke08</attr><inner>{{cite journal |author=Leweke FM, Koethe D |title=Cannabis and psychiatric disorders: it is not only addiction |journal=Addict Biol |volume=13 |issue=2 |pages=264–75 |date=June 2008  |pmid=18482435 |doi=10.1111/j.1369-1600.2008.00106.x |url=}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="4" i="8">====Developmental factors====</h>
Factors such as hypoxia and infection, or stress and malnutrition in the mother during [[fetal development]], may result in a slight increase in the risk of schizophrenia later in life.<ext><name>ref</name><attr> name=Lancet09</attr></ext> People diagnosed with schizophrenia are more likely to have been born in winter or spring (at least in the [[northern hemisphere]]), which may be a result of increased rates of viral exposures [[in utero]].<ext><name>ref</name><attr> name=BMJ07</attr></ext> The increased risk is about 5 to 8%.<ext><name>ref</name><attr> name=yolken</attr><inner>{{cite journal|journal=Herpes |date=Jun 2004 |volume=11 |issue=Suppl 2 |pages=83A–88A  |title=Viruses and schizophrenia: a focus on herpes simplex virus|author=Yolken R. |pmid=15319094}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="9">==Mechanisms==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Mechanisms of schizophrenia</value></part></template>
A number of attempts have been made to explain the link between altered brain function and schizophrenia.<ext><name>ref</name><attr> name=Lancet09</attr></ext> One of the most common is the [[Dopamine hypothesis of schizophrenia|dopamine hypothesis]], which attributes psychosis to the mind's faulty interpretation of the misfiring of [[dopamine|dopaminergic neurons]].<ext><name>ref</name><attr> name=Lancet09</attr></ext>

<h level="3" i="10">===Psychological===</h>
Many psychological mechanisms have been implicated in the development and maintenance of schizophrenia. [[Cognitive bias]]es have been identified in those with the diagnosis or those at risk, especially when under stress or in confusing situations.<ext><name>ref</name><attr/><inner>{{cite journal |author=Broome MR, Woolley JB, Tabraham P, et al. |title=What causes the onset of psychosis? |journal=Schizophr. Res. |volume=79 |issue=1 |pages=23–34 |date=November 2005  |pmid=16198238 |doi=10.1016/j.schres.2005.02.007}}</inner><close>&lt;/ref&gt;</close></ext> Some cognitive features may reflect global [[neurocognitive deficit]]s such as memory loss, while others may be related to particular issues and experiences.<ext><name>ref</name><attr> name=&quot;Bentall_et_al_2007&quot;</attr><inner>{{cite journal |author=Bentall RP, Fernyhough C, Morrison AP, Lewis S, Corcoran R |year=2007 |title=Prospects for a cognitive-developmental account of psychotic experiences |journal=Br J Clin Psychol |volume=46 | issue=Pt 2 |pages=155–73 |pmid=17524210 | doi = 10.1348/014466506X123011}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=&quot;Kurtz_2005&quot;</attr><inner>{{cite journal |author=Kurtz MM |year=2005 |title=Neurocognitive impairment across the lifespan in schizophrenia: an update |journal=[[Schizophrenia Research]] |volume=74 | issue=1 |pages=15–26 |pmid=15694750 |doi=10.1016/j.schres.2004.07.005}}</inner><close>&lt;/ref&gt;</close></ext>

Despite a demonstrated appearance of blunted effect, recent findings indicate that many individuals diagnosed with schizophrenia are emotionally responsive, particularly to stressful or negative stimuli, and that such sensitivity may cause vulnerability to symptoms or to the disorder.<ext><name>ref</name><attr> name=&quot;schizophrenia1&quot;</attr><inner>{{cite journal |author=Cohen AS, Docherty NM |year=2004 |title=Affective reactivity of speech and emotional experience in patients with schizophrenia |journal=[[Schizophrenia Research]] |volume=69 | issue=1 |pages=7–14 |pmid=15145465 |doi=10.1016/S0920-9964(03)00069-0 }}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Horan WP, Blanchard JJ |year=2003 |title=Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping |journal=[[Schizophrenia Research]] |volume=60 | issue=2–3 |pages=271–83 |pmid=12591589 |doi=10.1016/S0920-9964(02)00227-X}}</inner><close>&lt;/ref&gt;</close></ext> Some evidence suggests that the content of delusional beliefs and psychotic experiences can reflect emotional causes of the disorder, and that how a person interprets such experiences can influence symptomatology.<ext><name>ref</name><attr/><inner>{{cite journal |author=Smith B, Fowler DG, Freeman D, et al. |title=Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations |journal=Schizophr. Res. |volume=86 |issue=1–3 |pages=181–8 |date=September 2006  |pmid=16857346 |doi=10.1016/j.schres.2006.06.018}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Beck, AT |year=2004 |title=A Cognitive Model of Schizophrenia |journal=Journal of Cognitive Psychotherapy |volume=18 | issue=3 |pages=281–88 | doi = 10.1891/jcop.18.3.281.65649}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Bell V, Halligan PW, Ellis HD |year=2006 |title=Explaining delusions: a cognitive perspective |journal=[[Trends (journals)|Trends in Cognitive Science]] |volume=10 | issue=5 |pages=219–26 |pmid=16600666 |doi=10.1016/j.tics.2006.03.004}}</inner><close>&lt;/ref&gt;</close></ext> The use of &quot;[[safety|safety behaviors]]&quot; to avoid imagined threats may contribute to the [[Chronic (medicine)|chronicity]] of delusions.<ext><name>ref</name><attr> name=&quot;Freeman_BRT_2007&quot;</attr><inner>{{cite journal |author=Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE, Dunn G |title=Acting on persecutory delusions: the importance of safety seeking |journal=Behav Res Ther |volume=45 |issue=1 |pages=89–99 |date=January 2007  |pmid=16530161 |doi=10.1016/j.brat.2006.01.014 |url=}}</inner><close>&lt;/ref&gt;</close></ext> Further evidence for the role of psychological mechanisms comes from the effects of [[psychotherapies]] on symptoms of schizophrenia.<ext><name>ref</name><attr/><inner>{{cite journal |author=Kuipers E, Garety P, Fowler D, Freeman D, Dunn G, Bebbington P |title=Cognitive, emotional, and social processes in psychosis: refining cognitive behavioral therapy for persistent positive symptoms |journal=Schizophr Bull |volume=32 Suppl 1 |pages=S24–31 |date=October 2006  |pmid=16885206 |pmc=2632539 |doi=10.1093/schbul/sbl014 }}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="11">===Neurological===</h>
[[File:Schizophrenia fMRI working memory.jpg|thumb|[[Functional magnetic resonance imaging]] (fMRI) and other [[brain imaging]] technologies allow for the study of differences in brain activity in people diagnosed with schizophrenia. The image shows two levels of the brain, with areas that were more active in healthy controls than in schizophrenia patients shown in orange, during an fMRI study of working memory.]]

Schizophrenia is associated with subtle differences in brain structures, found in 40 to 50% of cases, and in brain chemistry during acute psychotic states.<ext><name>ref</name><attr> name=Lancet09</attr></ext> Studies using [[neuropsychological test]]s and [[brain imaging]] technologies such as [[Functional magnetic resonance imaging|fMRI]] and [[Positron emission tomography|PET]] to examine functional differences in brain activity have shown that differences seem to most commonly occur in the  [[frontal lobe]]s, [[hippocampus]] and [[temporal lobe]]s.<ext><name>ref</name><attr/><inner>{{cite book |year=2006 |author=Kircher, Tilo and Renate Thienel |title=The Boundaries of Consciousness |isbn=0-444-52876-8 |page=302 |url=http://books.google.com/?id=YHGacGKyVbYC&amp;pg=PA302 |chapter=Functional brain imaging of symptoms and cognition in schizophrenia |publisher=Elsevier |location=Amsterdam}}</inner><close>&lt;/ref&gt;</close></ext>  Reductions in brain volume, smaller than those found in [[Alzheimer's disease]], have been reported in areas of the frontal cortex and temporal lobes. It is uncertain whether these volumetric changes are progressive or preexist prior to the onset of the disease.<ext><name>ref</name><attr> name=Coyle</attr></ext>  These differences have been linked to the [[neurocognitive deficit]]s often associated with schizophrenia.<ext><name>ref</name><attr> name=&quot;Green2006&quot;</attr><inner>{{cite journal |author=Green MF |year=2006 |title=Cognitive impairment and functional outcome in schizophrenia and bipolar disorder|journal=Journal of Clinical Psychiatry |volume=67 | issue=Suppl 9 |pages=3–8 |pmid=16965182 |doi=10.4088/jcp.1006e12}}</inner><close>&lt;/ref&gt;</close></ext>  Because neural circuits are altered, it has alternatively been suggested that schizophrenia should be thought of as a collection of neurodevelopmental disorders.<ext><name>ref</name><attr> name=Insel_2010</attr><inner>{{cite journal |author=Insel TR |title=Rethinking schizophrenia |journal=Nature |volume=468 |issue=7321 |pages=187–93 |date=November 2010  |pmid=21068826 |doi=10.1038/nature09552 }}</inner><close>&lt;/ref&gt;</close></ext> There has been debate on whether treatment with antipsychotics can itself cause reduction of brain volume.<ext><name>ref</name><attr/><inner>{{cite web|title=Antipsychotics for schizophrenia associated with subtle loss in brain volume|url=http://www.sciencedaily.com/releases/2011/02/110207165438.htm|website=ScienceDaily|accessdate=3 July 2014|date=February 8, 2011}}</inner><close>&lt;/ref&gt;</close></ext>

Particular attention has been paid to the function of dopamine in the [[mesolimbic pathway]] of the brain. This focus largely resulted from the accidental finding that [[phenothiazine]] drugs, which block dopamine function, could reduce psychotic symptoms. It is also supported by the fact that amphetamines, which trigger the release of dopamine, may exacerbate the psychotic symptoms in schizophrenia.<ext><name>ref</name><attr> name=&quot;Laruelle_et_al_1996&quot;</attr><inner>{{cite journal |author=Laruelle M, Abi-Dargham A, van Dyck CH, et al. |title=Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=93 |issue=17 |pages=9235–40 |date=August 1996  |pmid=8799184 |pmc=38625 |doi= 10.1073/pnas.93.17.9235}}</inner><close>&lt;/ref&gt;</close></ext> The influential dopamine hypothesis of schizophrenia proposed that excessive activation of [[Dopamine receptor D2|D&lt;sub&gt;2&lt;/sub&gt; receptors]] was the cause of (the positive symptoms of) schizophrenia. Although postulated for about 20&amp;nbsp;years based on the D&lt;sub&gt;2&lt;/sub&gt; blockade effect common to all antipsychotics, it was not until the mid-1990s that [[Positron emission tomography|PET]] and [[SPET]] imaging studies provided supporting evidence. The dopamine hypothesis is now thought to be simplistic, partly because newer antipsychotic medication ([[atypical antipsychotic]] medication) can be just as effective as older medication ([[typical antipsychotic]] medication), but also affects [[serotonin]] function and may have slightly less of a dopamine blocking effect.<ext><name>ref</name><attr> name=&quot;JonesPilowsky2002&quot;</attr><inner>{{cite journal |author=Jones HM, Pilowsky LS |year=2002 |title=Dopamine and antipsychotic drug action revisited |journal=[[British Journal of Psychiatry]] |volume=181 |pages=271–275 |pmid=12356650 |doi=10.1192/bjp.181.4.271}}</inner><close>&lt;/ref&gt;</close></ext>

Interest has also focused on the neurotransmitter [[glutamate]] and the reduced function of the [[NMDA receptor|NMDA glutamate receptor]] in schizophrenia, largely because of the abnormally low levels of [[glutamate receptor]]s found in the postmortem brains of those diagnosed with schizophrenia,<ext><name>ref</name><attr> name=&quot;fn_27&quot;</attr><inner>{{cite journal |author=Konradi C, Heckers S |year=2003 |title=Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment |journal=Pharmacology and Therapeutics |volume=97 |issue=2 |pages=153–79 |pmid=12559388 |doi=10.1016/S0163-7258(02)00328-5 }}</inner><close>&lt;/ref&gt;</close></ext> and the discovery that glutamate-blocking drugs such as [[phencyclidine]] and [[ketamine]] can mimic the symptoms and cognitive problems associated with the condition.<ext><name>ref</name><attr> name=&quot;fn_59&quot;</attr><inner>{{cite journal |author=Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA |year=2001 |title=Effects of ketamine in normal and schizophrenic volunteers |journal=[[Neuropsychopharmacology]] |volume=25 |issue=4 |pages=455–67 |pmid=11557159 |doi=10.1016/S0893-133X(01)00243-3 }}</inner><close>&lt;/ref&gt;</close></ext> Reduced glutamate function is linked to poor performance on tests requiring frontal lobe and hippocampal function, and glutamate can affect dopamine function, both of which have been implicated in schizophrenia, have suggested an important mediating (and possibly causal) role of glutamate pathways in the condition.<ext><name>ref</name><attr> name=&quot;fn_28&quot;</attr><inner>{{cite journal |author=Coyle JT, Tsai G, Goff D |year=2003 |title=Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia |journal=Annals of the [[New York Academy of Sciences]] |volume=1003 |pages=318–27 |pmid=14684455 |doi=10.1196/annals.1300.020}}</inner><close>&lt;/ref&gt;</close></ext> But positive symptoms fail to respond to glutamatergic medication.<ext><name>ref</name><attr> name=&quot;fn_60&quot;</attr><inner>{{cite journal |author=Tuominen HJ, Tiihonen J, Wahlbeck K |year=2005 |title=Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis |journal=[[Schizophrenia Research]] |volume=72 |pages=225–34 |pmid=15560967 |doi=10.1016/j.schres.2004.05.005 |issue=2–3}}</inner><close>&lt;/ref&gt;</close></ext>
<template lineStart="1"><title>clear</title></template>

<h level="2" i="12">==Diagnosis==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Diagnosis of schizophrenia</value></part></template>
[[File:John Forbes Nash, Jr. by Peter Badge.jpg|thumb|upright|[[John Forbes Nash|John Nash]], an American [[mathematician]] and joint winner of the 1994 [[Nobel Memorial Prize in Economic Sciences|Nobel Prize for Economics]], who had schizophrenia. His life was the subject of the 2001 [[Academy Award]]-winning film ''[[A Beautiful Mind (film)|A Beautiful Mind]]''.]]

Schizophrenia is diagnosed based on criteria in either the [[American Psychiatric Association]]'s fifth edition of the ''[[Diagnostic and Statistical Manual of Mental Disorders]]'' (DSM 5), or the [[World Health Organization]]'s [[ICD|International Statistical Classification of Diseases and Related Health Problems]] (ICD-10). These criteria use the self-reported experiences of the person and reported abnormalities in behavior, followed by a clinical assessment by a [[mental health professional]]. Symptoms associated with schizophrenia occur along a continuum in the population and must reach a certain severity before a diagnosis is made.<ext><name>ref</name><attr> name=BMJ07</attr></ext> As of 2013 there is no objective test.<ext><name>ref</name><attr> name=DSM5pg101</attr><inner>{{cite book| author= American Psychiatric Association |title= Diagnostic and Statistical Manual of Mental Disorders |publisher= American Psychiatric Publishing |location= Arlington |isbn= 978-0890425558 |pages= 101–05 |edition=5th}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="13">===Criteria===</h>
In 2013, the American Psychiatric Association released the fifth edition of the DSM ([[DSM-5]]). To be diagnosed with schizophrenia, two diagnostic criteria have to be met over much of the time of a period of at least one month, with a significant impact on social or occupational functioning for at least six months. The person had to be suffering from delusions, hallucinations or disorganized speech. A second symptom could be negative symptoms or severely disorganized or catatonic behaviour.<ext><name>ref</name><attr> name=&quot;DSM5pgxx&quot;</attr><inner>{{cite book| author= American Psychiatric Association |title= Diagnostic and Statistical Manual of Mental Disorders |publisher= American Psychiatric Publishing |location= Arlington |isbn= 978-0890425558 |pages=  |edition=5th}}</inner><close>&lt;/ref&gt;</close></ext> The definition of schizophrenia remained essentially the same as that specified by the 2000 version of DSM (DSM-IV-TR), but DSM-5 makes a number of changes.
* Subtype classifications&amp;nbsp;– such as catatonic and [[paranoid schizophrenia]] &amp;nbsp;– are removed. These were retained in previous revisions largely for reasons of tradition, but had subsequently proved to be of little worth.<ext><name>ref</name><attr> name=tandon</attr></ext>
* [[Catatonia]] is no longer so strongly associated with schizophrenia.<ext><name>ref</name><attr> name=cataonia-dsm</attr><inner>As referenced from PMID 23800613, {{cite journal |author=Heckers S, Tandon R, Bustillo J |title=Catatonia in the DSM--shall we move or not? |journal=Schizophr Bull |volume=36 |issue=2 |pages=205–7 |date=March 2010  |pmid=19933711 |pmc=2833126 |doi=10.1093/schbul/sbp136 |type=Editorial}}</inner><close>&lt;/ref&gt;</close></ext>
* In describing a person's schizophrenia, it is recommended that a better distinction be made between the current state of the condition and its historical progress, to achieve a clearer overall characterization.<ext><name>ref</name><attr> name=tandon</attr></ext>
* Special treatment of [[Schneider's first-rank symptoms]] is no longer recommended.<ext><name>ref</name><attr> name=tandon</attr></ext>
* [[Schizoaffective disorder]] is better defined to demarcate it more cleanly from schizophrenia.<ext><name>ref</name><attr> name=tandon</attr><inner>{{cite journal |author=Tandon R, Gaebel W, Barch DM, et al. |title=Definition and description of schizophrenia in the DSM-5 |journal=Schizophr. Res. |volume=150 |issue=1 |pages=3–10 |date=October 2013  |pmid=23800613 |doi=10.1016/j.schres.2013.05.028}}</inner><close>&lt;/ref&gt;</close></ext>
* An assessment covering eight domains of [[psychopathology]]&amp;nbsp;– such as whether hallucination or mania is experienced&amp;nbsp;– is recommended to help clinical decision-making.<ext><name>ref</name><attr> name=dimensions</attr><inner>{{cite journal |author=Barch DM, Bustillo J, Gaebel W, et al. |title=Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5 |journal=Schizophr. Res. |volume=150 |issue=1 |pages=15–20 |date=October 2013  |pmid=23706415 |doi=10.1016/j.schres.2013.04.027 }}</inner><close>&lt;/ref&gt;</close></ext>

The ICD-10 criteria are typically used in European countries, while the DSM criteria are used in the United States and to varying degrees around the world, and are prevailing in research studies. The ICD-10 criteria put more emphasis on Schneiderian first-rank symptoms. In practice, agreement between the two systems is high.<ext><name>ref</name><attr> name=&quot;Jakobsen_et_al_2005&quot;</attr><inner>{{cite journal |author=Jakobsen KD, Frederiksen JN, Hansen T, et al. |year=2005 |title=Reliability of clinical ICD-10 schizophrenia diagnoses |journal=Nordic Journal of Psychiatry |volume=59 | issue=3 |pages=209–12 |pmid=16195122 | doi = 10.1080/08039480510027698}}</inner><close>&lt;/ref&gt;</close></ext>

If signs of disturbance are present for more than a month but less than six months, the diagnosis of [[schizophreniform disorder]] is applied. Psychotic symptoms lasting less than a month may be diagnosed as [[brief psychotic disorder]], and various conditions may be classed as [[psychotic disorder not otherwise specified]], while [[schizoaffective disorder]] is diagnosed if symptoms of [[mood disorder]] are substantially present alongside psychotic symptoms. If the psychotic symptoms are the direct physiological result of a general medical condition or a substance, then the diagnosis is one of a psychosis secondary to that condition.<ext><name>ref</name><attr> name=&quot;DSM5pgxx&quot;</attr></ext><comment>&lt;!-- cites oprevious three sentences --&gt;</comment> Schizophrenia is not diagnosed if symptoms of [[pervasive developmental disorder]] are present unless prominent delusions or hallucinations are also present.<ext><name>ref</name><attr> name=&quot;DSM5pgxx&quot;</attr></ext><comment>&lt;!-- will be different page to preceding ref --&gt;</comment>

<h level="3" i="14">===Subtypes===</h>
The DSM-5 work group proposed dropping the five sub-classifications of schizophrenia included in DSM-IV-TR:<ext><name>ref</name><attr/><inner>[[American Psychiatric Association]] DSM-5 Work Groups (2010) [http://www.dsm5.org/ProposedRevisions/Pages/SchizophreniaandOtherPsychoticDisorders.aspx Proposed Revisions – Schizophrenia and Other Psychotic Disorders]. Retrieved 17 February 2010.</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=WHOICD</attr></ext>
* [[Paranoid schizophrenia|Paranoid type]]: Delusions or auditory hallucinations are present, but thought disorder, disorganized behavior, or affective flattening are not. Delusions are persecutory and/or grandiose, but in addition to these, other themes such as jealousy, religiosity, or [[somatization]] may also be present. (DSM code 295.3/ICD code F20.0)
* [[Disorganized schizophrenia|Disorganized type]]: Named ''hebephrenic schizophrenia'' in the ICD. Where thought disorder and flat affect are present together. (DSM code 295.1/ICD code F20.1)
* [[Catatonia|Catatonic type]]: The subject may be almost immobile or exhibit agitated, purposeless movement. Symptoms can include catatonic stupor and [[waxy flexibility]]. (DSM code 295.2/ICD code F20.2)
* Undifferentiated type: Psychotic symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not been met. (DSM code 295.9/ICD code F20.3)
* Residual type: Where positive symptoms are present at a low intensity only. (DSM code 295.6/ICD code F20.5)

The ICD-10 defines two additional subtypes:<ext><name>ref</name><attr> name=WHOICD</attr><inner>{{cite web |url=http://www.who.int/classifications/icd/en/GRNBOOK.pdf |title=The ICD-10 Classification of Mental and Behavioural Disorders |format= PDF |publisher=World Health Organization |page=26}}</inner><close>&lt;/ref&gt;</close></ext>
* Post-schizophrenic depression: A depressive episode arising in the aftermath of a schizophrenic illness where some low-level schizophrenic symptoms may still be present. (ICD code F20.4)
* [[Simple-type schizophrenia|Simple schizophrenia]]: Insidious and progressive development of prominent negative symptoms with no history of psychotic episodes. (ICD code F20.6)
[[Sluggish schizophrenia]] is in the Russian version of the ICD-10. &quot;Sluggish schizophrenia&quot; is in the category of &quot;schizotypal&quot; disorder in section F21 of chapter V.<ext><name>ref</name><attr/><inner>{{vcite web|title=МКБ-10: Классификация психических и поведенческих расстройств. F21 Шизотипическое расстройство|trans_title=The ICD-10 Classification of Mental and Behavioural Disorders. F21 Schizotypal Disorder|url=http://www.talagi.ru/library/mkb10_f2.htm#f21|language=Russian|harvid=Russian adapted version of the ICD-10}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="15">===Differential===</h>
<template lineStart="1"><title>see also</title><part><name index="1"/><value>Dual diagnosis</value></part><part><name index="2"/><value>Comparison of bipolar disorder and schizophrenia</value></part></template>
Psychotic symptoms may be present in several other mental disorders, including [[bipolar disorder]],<ext><name>ref</name><attr/><inner>{{cite journal |author=Pope HG |year=1983 |title=Distinguishing bipolar disorder from schizophrenia in clinical practice: guidelines and case reports |journal=Hospital and Community Psychiatry |volume=34 |pages=322–28 |accessdate= 24 February 2008}}</inner><close>&lt;/ref&gt;</close></ext> [[borderline personality disorder]],<ext><name>ref</name><attr/><inner>{{cite journal |author=McGlashan TH |title=Testing DSM-III symptom criteria for schizotypal and borderline personality disorders |journal=[[Archives of General Psychiatry]] |volume=44 |issue=2 |pages=143–8 |date=February 1987  |pmid=3813809 |doi=10.1001/archpsyc.1987.01800140045007}}</inner><close>&lt;/ref&gt;</close></ext> drug intoxication and [[Substance-induced psychosis|drug-induced psychosis]]. Delusions (&quot;non-bizarre&quot;) are also present in [[delusional disorder]], and social withdrawal in [[social anxiety disorder]], [[avoidant personality disorder]] and [[schizotypal personality disorder]]. Schizotypal personality disorder has symptoms that are similar but less severe than those of schizophrenia.<ext><name>ref</name><attr> name=DSM5pg101</attr></ext> Schizophrenia occurs along with [[obsessive-compulsive disorder]] (OCD) considerably more often than could be explained by chance, although it can be difficult to distinguish obsessions that occur in OCD from the delusions of schizophrenia.<ext><name>ref</name><attr/><inner>{{cite journal |author=Bottas A |title=Comorbidity: Schizophrenia With Obsessive-Compulsive Disorder  |journal=Psychiatric Times |volume=26 |issue=4 |date=15 April 2009 |url=http://www.psychiatrictimes.com/display/article/10168/1402540 }}</inner><close>&lt;/ref&gt;</close></ext> A small number of people withdrawing from benzodiazepines experience a severe withdrawal syndrome which may last a long time.<comment>&lt;!-- &lt;ref name=&quot;gabbards&quot;&gt; --&gt;</comment> It can resemble schizophrenia and be misdiagnosed as such.<ext><name>ref</name><attr> name=&quot;gabbards&quot;</attr><inner>{{cite book | author=Gabbard GO | title = Gabbard's Treatments of Psychiatric Disorders, Fourth Edition (Treatments of Psychiatric Disorders) | date = 15 May 2007 | publisher = American Psychiatric Publishing | url=http://books.google.com/?id=-T2aEqfwLW4C&amp;pg=PA209 | isbn = 1-58562-216-8 | pages = 209–11 }}</inner><close>&lt;/ref&gt;</close></ext>

A more general medical and neurological examination may be needed to rule out medical illnesses which may rarely produce psychotic schizophrenia-like symptoms, such as [[Metabolic disorder|metabolic disturbance]], [[systemic infection]], [[syphilis]], [[HIV]] infection, [[epilepsy]], and brain lesions.  [[Stroke]], [[multiple sclerosis]], [[hyperthyroidism]], [[hypothyroidism]] and [[dementia]]s such as [[Alzheimer's disease]], [[Huntington's disease]], [[frontotemporal dementia]] and [[Lewy Body dementia]] may also be associated with schizophrenia-like psychotic symptoms.<ext><name>ref</name><attr/><inner>{{cite book|title=Bradley's neurology in clinical practice|year=2012|publisher=Elsevier/Saunders|location=Philadelphia, PA|isbn=1-4377-0434-4|author=Murray ED, Buttner N, Price BH|volume=1|edition=6th|pages=92–111|editor=Bradley WG, Daroff RB, Fenichel GM, Jankovic J|chapter=Depression and Psychosis in Neurological Practice}}</inner><close>&lt;/ref&gt;</close></ext> It may be necessary to rule out a [[delirium]], which can be distinguished by visual hallucinations, acute onset and fluctuating [[level of consciousness]], and indicates an underlying medical illness. Investigations are not generally repeated for relapse unless there is a specific ''medical'' indication or possible [[adverse effects]] from [[antipsychotic medication]]. In children hallucinations must be separated from normal childhood fantasies.<ext><name>ref</name><attr> name=DSM5pg101</attr></ext>

<h level="2" i="16">==Prevention==</h>
[[Mental disorder#Prevention|Prevention]] of schizophrenia is difficult as there are no reliable markers for the later development of the disease.<ext><name>ref</name><attr> name=&quot;Cannon_et_al_2007&quot;</attr><inner>{{cite journal |author=Cannon TD, Cornblatt B, McGorry P |title=The empirical status of the ultra high-risk (prodromal) research paradigm |journal=Schizophrenia Bulletin |volume=33 |issue=3 |pages=661–4 |date=May 2007  |pmid=17470445 |doi=10.1093/schbul/sbm031 |pmc=2526144}}</inner><close>&lt;/ref&gt;</close></ext> There is tentative evidence for the effectiveness of early interventions to prevent schizophrenia.<ext><name>ref</name><attr/><inner>{{cite journal|last1=Marshall|first1=M|last2=Rathbone|first2=J|title=Early intervention for psychosis.|journal=The Cochrane database of systematic reviews|date=Jun 15, 2011|issue=6|pages=CD004718|pmid=21678345}}</inner><close>&lt;/ref&gt;</close></ext> While there is some evidence that early intervention in those with a [[psychotic]] episode may improve short-term outcomes, there is little benefit from these measures after five years.<ext><name>ref</name><attr> name=Lancet09</attr></ext> Attempting to prevent schizophrenia in the [[prodrome]] phase is of uncertain benefit and therefore as of 2009 is not recommended.<ext><name>ref</name><attr/><inner>{{cite journal |author=de Koning MB, Bloemen OJ, van Amelsvoort TA, et al. |title=Early intervention in patients at ultra high risk of psychosis: benefits and risks |journal=Acta Psychiatr Scand |volume=119 |issue=6 |pages=426–42 |date=June 2009  |pmid=19392813 |doi=10.1111/j.1600-0447.2009.01372.x |url=}}</inner><close>&lt;/ref&gt;</close></ext> [[Cognitive behavioral therapy]] may reduce the risk of psychosis in those at high risk after a year<ext><name>ref</name><attr/><inner>{{cite journal|author=Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T|title=Early interventions to prevent psychosis: systematic review and meta-analysis|journal=BMJ (Clinical research ed.)|date=18 January 2013|volume=346|pages=f185|pmid=23335473|pmc=3548617|doi=10.1136/bmj.f185}}</inner><close>&lt;/ref&gt;</close></ext> and is recommended by the [[National Institute for Health and Care Excellence|National Institute for Health and Care Excellence (NICE)]] in this group.<ext><name>ref</name><attr/><inner>{{cite web|title=Psychosis and schizophrenia in adults: treatment and management|url=http://www.nice.org.uk/nicemedia/live/14382/66534/66534.pdf|work=NICE|accessdate=19 April 2014|page=7|date=Mar 2014}}</inner><close>&lt;/ref&gt;</close></ext> Another preventative measure is to avoid drugs that have been associated with development of the disorder, including [[cannabis (drug)|cannabis]], [[cocaine]], and [[amphetamines]].<ext><name>ref</name><attr> name=BMJ07</attr><inner>{{cite journal |author=Picchioni MM, Murray RM |title=Schizophrenia |journal=BMJ |volume=335 |issue=7610 |pages=91–5 |date=July 2007  |pmid=17626963 |pmc=1914490 |doi=10.1136/bmj.39227.616447.BE}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="17">==Management==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Management of schizophrenia</value></part></template>
The primary treatment of schizophrenia is antipsychotic medications, often in combination with psychological and social supports.<ext><name>ref</name><attr> name=Lancet09</attr></ext> Hospitalization may occur for severe episodes either [[voluntary commitment|voluntarily]] or (if mental health legislation allows it) [[involuntary commitment|involuntarily]]. Long-term hospitalization is uncommon since [[deinstitutionalization]] beginning in the 1950s, although it still occurs.<ext><name>ref</name><attr> name=&quot;BeckerKilian2006&quot; </attr></ext> Community support services including drop-in centers, visits by members of a [[Community mental health service|community mental health team]], supported employment<ext><name>ref</name><attr/><inner>{{cite journal | author = McGurk SR, Mueser KT, Feldman K,  Wolfe R, Pascaris A | title = Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. | journal = American Journal of Psychiatry | volume = 164 | issue = 3 | pages = 437–41 |date=Mar 2007 | url = http://ajp.psychiatryonline.org/cgi/content/full/164/3/437 | doi = 10.1176/appi.ajp.164.3.437 | pmid = 17329468 }}</inner><close>&lt;/ref&gt;</close></ext> and support groups are common. Some evidence indicates that regular exercise has a positive effect on the physical and mental health of those with schizophrenia.<ext><name>ref</name><attr/><inner>{{cite journal |author=Gorczynski P, Faulkner G |title=Exercise therapy for schizophrenia |journal=Cochrane Database of Systematic Reviews |issue=5 |pages=CD004412 |year=2010 |pmid=20464730 |doi=10.1002/14651858.CD004412.pub2 |url=}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="18">===Medication===</h>
[[File:Risperdal tablets.jpg|thumb|left|upright|[[Risperidone]] (trade name Risperdal) is a common [[atypical antipsychotic]] medication.]]
The first-line psychiatric treatment for schizophrenia is antipsychotic medication,<ext><name>ref</name><attr> name=&quot;fn_72&quot;</attr><inner>{{cite web |url=http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf |title= Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care |accessdate=25 November 2009 |author=National Collaborating Centre for Mental Health |date=25 March 2009 }}</inner><close>&lt;/ref&gt;</close></ext> which can reduce the positive symptoms of psychosis in about 7 to 14 days. Antipsychotics, however, fail to significantly ameliorate the negative symptoms and cognitive dysfunction.<ext><name>ref</name><attr> name=AFP10</attr></ext><ext><name>ref</name><attr> name=&quot;pmid18291627&quot;</attr><inner>{{cite journal |author=Tandon R, Keshavan MS, Nasrallah HA |title=Schizophrenia, &quot;Just the Facts&quot;: what we know in 2008 part 1: overview |journal=[[Schizophrenia Research]] |volume=100 |issue=1–3 |pages=4–19 |date=March 2008  |pmid=18291627 |doi=10.1016/j.schres.2008.01.022 |url=http://download.journals.elsevierhealth.com/pdfs/journals/0920-9964/PIIS0920996408000716.pdf}}</inner><close>&lt;/ref&gt;</close></ext> In those on antipsychotics, continued use decreases the risk of relapse.<ext><name>ref</name><attr> name=Relapse2012</attr><inner>{{cite journal |author=Leucht S, Tardy M, Komossa K, et al. |title=Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis |journal=Lancet |volume=379 |issue=9831 |pages=2063–71 |date=June 2012  |pmid=22560607 |doi=10.1016/S0140-6736(12)60239-6 }}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=Harrow2013</attr></ext> There is little evidence regarding consistent benefits from their use beyond two or three years.<ext><name>ref</name><attr> name=Harrow2013</attr></ext>

The choice of which antipsychotic to use is based on benefits, risks, and costs.<ext><name>ref</name><attr> name=Lancet09</attr></ext> It is debatable whether, as a class, [[typical antipsychotics|typical]] or [[atypical antipsychotics]] are better,<ext><name>ref</name><attr/><inner>{{cite journal |author=Kane JM, Correll CU |title=Pharmacologic treatment of schizophrenia |journal=Dialogues Clin Neurosci |volume=12 |issue=3 |pages=345–57 |year=2010 |pmid=20954430 |pmc=3085113}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Hartling L, Abou-Setta AM, Dursun S, et al. |title=Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-generation versus second-generation medications: a systematic review and meta-analysis |journal=Annals of Internal Medicine|date=14 August 2012|pmid=22893011|doi=10.7326/0003-4819-157-7-201210020-00525 |volume=157 |issue=7 |pages=498–511}}</inner><close>&lt;/ref&gt;</close></ext> though there is evidence of [[amisulpride]], [[olanzapine]], [[risperidone]] and [[clozapine]] being the most effective medications.<ext><name>ref</name><attr> name=&quot;barry 2012&quot;</attr></ext> Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages.<ext><name>ref</name><attr> name=AFP07</attr><inner>{{cite journal |author=Schultz SH, North SW, Shields CG |title=Schizophrenia: a review |journal=Am Fam Physician |volume=75 |issue=12 |pages=1821–9 |date=June 2007  |pmid=17619525}}</inner><close>&lt;/ref&gt;</close></ext> There is a good response in 40–50%, a partial response in 30–40%, and treatment resistance (failure of symptoms to respond satisfactorily after six weeks to two or three different antipsychotics) in 20% of people.<ext><name>ref</name><attr> name=AFP10</attr></ext> Clozapine is an effective treatment for those who respond poorly to other drugs (&quot;treatment-resistant&quot; or &quot;refractory&quot; schizophrenia),<ext><name>ref</name><attr/><inner>{{cite journal |author=Taylor DM |title=Refractory schizophrenia and atypical antipsychotics |journal=J Psychopharmacol |volume= 14|issue=4 |pages=409–418 |year=2000 |doi=10.1177/026988110001400411 }}</inner><close>&lt;/ref&gt;</close></ext> but it has the potentially serious side effect of [[agranulocytosis]] (lowered [[white blood cell]] count) in less than 4% of people.<ext><name>ref</name><attr> name=BMJ07</attr></ext><ext><name>ref</name><attr> name=Lancet09</attr></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Essali A, Al-Haj Haasan N, Li C, Rathbone J |title=Clozapine versus typical neuroleptic medication for schizophrenia |journal=Cochrane Database of Systematic Reviews |volume= |issue=1 |pages=CD000059 |year=2009 |pmid=19160174 |doi=10.1002/14651858.CD000059.pub2 }}</inner><close>&lt;/ref&gt;</close></ext>

Most people on antipsychotics get side effects. People on typical antipsychotics tend to have a higher rate of [[extrapyramidal side effects]] while some atypicals are associated with considerable weight gain, diabetes and risk of [[metabolic syndrome]]; this is most pronounced with olanzapine, while risperidone and [[quetiapine]] are also associated with weight gain.<ext><name>ref</name><attr> name=&quot;barry 2012&quot;</attr><inner>{{cite journal|last=Barry SJE, Gaughan TM, Hunter R|date=2012|title=Schizophrenia|journal=BMJ Clinical Evidence|pmid=    23870705|url=http://www.clinicalevidence.bmj.com/x/systematic-review/1007/archive/06/2012.html}}</inner><close>&lt;/ref&gt;</close></ext> Risperidone has a similar rate of extrapyramidal symptoms to haloperidol.<ext><name>ref</name><attr> name=&quot;barry 2012&quot;</attr></ext>

It remains unclear whether the newer antipsychotics reduce the chances of developing [[neuroleptic malignant syndrome]] or [[tardive dyskinesia]], a rare but serious neurological disorder.<ext><name>ref</name><attr> name=&quot;Ananth_et_al_2004&quot;</attr><inner>{{cite journal |author=Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T |title=Neuroleptic malignant syndrome and atypical antipsychotic drugs |journal=Journal of Clinical Psychiatry |volume=65 |issue=4 |pages=464–70 |date=April 2004  |pmid=15119907 |doi=10.4088/JCP.v65n0403}}</inner><close>&lt;/ref&gt;</close></ext>

For people who are unwilling or unable to take medication regularly, long-acting [[Typical antipsychotic#Depot injections|depot]] preparations of antipsychotics may be used to achieve control.<ext><name>ref</name><attr> name=Depo06</attr><inner>{{cite journal |author=McEvoy JP |title=Risks versus benefits of different types of long-acting injectable antipsychotics |journal=J Clin Psychiatry |volume=67 Suppl 5 |issue= |pages=15–8 |year=2006 |pmid=16822092}}</inner><close>&lt;/ref&gt;</close></ext> They reduce the risk of relapse to a greater degree than oral medications.<ext><name>ref</name><attr> name=Relapse2012</attr></ext> When used in combination with psychosocial interventions they may improve long-term adherence to treatment.<ext><name>ref</name><attr> name=Depo06</attr></ext> The [[American Psychiatric Association]] suggests considering stopping antipsychotics in some people if there are no symptoms for more than a year.<ext><name>ref</name><attr> name=Harrow2013</attr><inner>{{cite journal| author= Harrow M, Jobe TH|title=Does long-term treatment of dchizophrenia with antipsychotic medications facilitate recovery?|journal=Schizophrenia bulletin|date=19 March 2013|pmid=23512950|volume=39|issue=5|pages=962–5|doi=10.1093/schbul/sbt034|pmc=3756791}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="3" i="19">===Psychosocial===</h>
A number of psychosocial interventions may be useful in the treatment of schizophrenia including: [[family therapy]],<ext><name>ref</name><attr> name=FT10</attr><inner>{{cite journal |author=Pharoah F, Mari J, Rathbone J, Wong W |title=Family intervention for schizophrenia |journal=Cochrane Database of Systematic Reviews |volume=12 |pages=CD000088 |year=2010 |pmid=21154340 |doi=10.1002/14651858.CD000088.pub3 |issue=12}}</inner><close>&lt;/ref&gt;</close></ext> [[assertive community treatment]], supported employment, [[cognitive remediation]],<ext><name>ref</name><attr> name=&quot;Medalia-2009&quot;</attr><inner>{{cite journal | author= Medalia A, Choi J| title = Cognitive remediation in schizophrenia. | journal = Neuropsychology Rev | url = http://www.brown.uk.com/schizophrenia/medalia.pdf | volume = 19 |issue = 3 | pages = 353–364 | year = 2009 | doi = 10.1007/s11065-009-9097-y | pmid = 19444614}}</inner><close>&lt;/ref&gt;</close></ext> skills training, token economic interventions, and psychosocial interventions for substance use and weight management.<ext><name>ref</name><attr> name=PORT09</attr><inner>{{cite journal |author=Dixon LB, Dickerson F, Bellack AS, et al. |title=The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements |journal=Schizophr Bull |volume=36 |issue=1 |pages=48–70 |date=January 2010  |pmid=19955389 |doi=10.1093/schbul/sbp115 |pmc=2800143}}</inner><close>&lt;/ref&gt;</close></ext> Family therapy or education, which addresses the whole family system of an individual, may reduce relapses and hospitalizations.<ext><name>ref</name><attr> name=FT10</attr></ext> Evidence for the effectiveness of cognitive-behavioral therapy (CBT) in either reducing symptoms or preventing relapse is minimal.<ext><name>ref</name><attr/><inner>{{cite journal|author=Jauhar S, McKenna PJ, Radua J, et al.|title=Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias|journal=The British journal of psychiatry : the journal of mental science|date=January 2014|volume=204|pages=20–9|pmid=24385461|type=Review|doi=10.1192/bjp.bp.112.116285|issue=1}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C |title=Cognitive behaviour therapy for schizophrenia |journal=Cochrane Database of Systematic Reviews |volume= |issue=4 |pages=CD000524 |year=2004 |pmid=15495000 |doi=10.1002/14651858.CD000524.pub2 |url=}}</inner><close>&lt;/ref&gt;</close></ext> Art or drama therapy have not been well-researched.<ext><name>ref</name><attr/><inner>{{cite journal | author = Ruddy R, Milnes D | title = Art therapy for schizophrenia or schizophrenia-like illnesses. | journal = Cochrane Database of Systematic Reviews | issue = 4 | pages = CD003728 | url = http://www.cochrane.org/reviews/en/ab003728.html | year = 2005 | doi = 10.1002/14651858.CD003728.pub2 | pmid = 16235338  }}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=&quot;Ruddy-2007&quot;</attr><inner>{{cite journal | author = Ruddy RA, Dent-Brown K| title = Drama therapy for schizophrenia or schizophrenia-like illnesses. | journal = Cochrane Database of Systematic Reviews | url = http://www.cochrane.org/reviews/en/ab005378.html | issue = 1 | pages = CD005378 | year = 2007 | doi = 10.1002/14651858.CD005378.pub2 | pmid = 17253555 }}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="20">==Prognosis==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Prognosis of schizophrenia</value></part></template>
Schizophrenia has great human and economic costs.<ext><name>ref</name><attr> name=Lancet09</attr></ext> It results in a decreased life expectancy by 10–25&amp;nbsp;years.<ext><name>ref</name><attr> name=Lauren2012</attr><inner>{{cite journal|author=Laursen TM, Munk-Olsen T, Vestergaard, M|title=Life expectancy and cardiovascular mortality in persons with schizophrenia|journal=Current opinion in psychiatry|date=March 2012|volume=25|issue=2|pages=83–8|pmid=22249081|doi=10.1097/YCO.0b013e32835035ca}}</inner><close>&lt;/ref&gt;</close></ext> This is primarily because of its association with [[obesity]], poor diet, sedentary lifestyles, and [[smoking]], with an increased rate of [[suicide]] playing a lesser role.<ext><name>ref</name><attr> name=Lancet09</attr></ext><ext><name>ref</name><attr> name=Lauren2012</attr></ext> Antipsychotic medications may also increase the risk.<ext><name>ref</name><attr> name=Lauren2012</attr></ext> These differences in life expectancy increased between the 1970s and 1990s.<ext><name>ref</name><attr> name=Mort07</attr><inner>{{cite journal |author=Saha S, Chant D, McGrath J |title=A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? |journal=Arch. Gen. Psychiatry |volume=64 |issue=10 |pages=1123–31 |date=October 2007  |pmid=17909124 |doi=10.1001/archpsyc.64.10.1123}}</inner><close>&lt;/ref&gt;</close></ext>

Schizophrenia is a major cause of [[disability]], with active psychosis ranked as the third-most-disabling condition after [[quadriplegia]] and [[dementia]] and ahead of [[paraplegia]] and [[blindness]].<ext><name>ref</name><attr> name=&quot;fn_35&quot;</attr><inner>{{cite journal |author=Ustun TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J, and the [[World Health Organization|WHO]]/[[National Institutes of Health|NIH]] Joint Project CAR Study Group |year=1999 |title=Multiple-informant ranking of the disabling effects of different health conditions in 14 countries |journal=[[The Lancet]] |volume=354 | issue=9173 |pages=111–15 |pmid=10408486 |doi=10.1016/S0140-6736(98)07507-2}}</inner><close>&lt;/ref&gt;</close></ext> Approximately three-fourths of people with schizophrenia have ongoing disability with relapses<ext><name>ref</name><attr> name=AFP10</attr><inner>{{cite journal |author=Smith T, Weston C, Lieberman J |title=Schizophrenia (maintenance treatment) |journal=Am Fam Physician |volume=82 |issue=4 |pages=338–9 |date=August 2010  |pmid=20704164 }}</inner><close>&lt;/ref&gt;</close></ext> and 16.7&amp;nbsp;million people globally are deemed to have moderate or severe disability from the condition.<ext><name>ref</name><attr/><inner>{{cite book|author=World Health Organization|title=The global burden of disease : 2004 update |year=2008|publisher=World Health Organization|location=Geneva, Switzerland|isbn=9789241563710|pages=35|edition=[Online-Ausg.]}}</inner><close>&lt;/ref&gt;</close></ext> Some people do recover completely and others function well in society.<ext><name>ref</name><attr/><inner>{{cite journal |author=Warner R |title=Recovery from schizophrenia and the recovery model |journal=Current Opinion in Psychiatry |volume=22 |issue=4 |pages=374–80 |date=July 2009  |pmid=19417668 |doi=10.1097/YCO.0b013e32832c920b |url=}}</inner><close>&lt;/ref&gt;</close></ext> Most people with schizophrenia live independently with community support.<ext><name>ref</name><attr> name=Lancet09</attr></ext> In people with a first episode of psychosis a good long-term outcome occurs in 42%, an intermediate outcome in 35% and a poor outcome in 27%.<ext><name>ref</name><attr/><inner>{{cite journal |author=Menezes NM, Arenovich T, Zipursky RB |title=A systematic review of longitudinal outcome studies of first-episode psychosis |journal=Psychol Med |volume=36 |issue=10 |pages=1349–62 |date=October 2006  |pmid=16756689 |doi=10.1017/S0033291706007951 |url=}}</inner><close>&lt;/ref&gt;</close></ext> Outcomes for schizophrenia appear better in the [[developing world|developing]] than the [[developed world]].<ext><name>ref</name><attr> name=Isa07</attr><inner>{{cite journal |author=Isaac M, Chand P, Murthy P |title=Schizophrenia outcome measures in the wider international community |journal=Br J Psychiatry Suppl |volume=50 |issue= |pages=s71–7 |date=August 2007  |pmid=18019048 }}</inner><close>&lt;/ref&gt;</close></ext> These conclusions, however, have been questioned.<ext><name>ref</name><attr/><inner>{{cite journal |author=Cohen A, Patel V, Thara R, Gureje O |title=Questioning an axiom: better prognosis for schizophrenia in the developing world? |journal=Schizophr Bull |volume=34 |issue=2 |pages=229–44 |date=March 2008  |pmid=17905787 |pmc=2632419 |doi=10.1093/schbul/sbm105}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Burns J |title=Dispelling a myth: developing world poverty, inequality, violence and social fragmentation are not good for outcome in schizophrenia |journal=Afr J Psychiatry (Johannesbg) |volume=12 |issue=3 |pages=200–5 |date=August 2009  |pmid=19894340 |doi=10.4314/ajpsy.v12i3.48494}}</inner><close>&lt;/ref&gt;</close></ext>

There is a higher than average [[suicide]] rate associated with schizophrenia. This has been cited at 10%, but a more recent analysis revises the estimate to 4.9%, most often occurring in the period following onset or first hospital admission.<ext><name>ref</name><attr> name=Jop2010</attr></ext><ext><name>ref</name><attr/><inner>{{cite journal |author=Palmer BA, Pankratz VS, Bostwick JM |title=The lifetime risk of suicide in schizophrenia: a reexamination |journal=Archives of General Psychiatry|volume=62 |issue=3 |pages=247–53 |date=March 2005  |pmid=15753237 |doi=10.1001/archpsyc.62.3.247}}</inner><close>&lt;/ref&gt;</close></ext> Several times more (20 to 40%) attempt suicide at least once.<ext><name>ref</name><attr> name=DSM5pg101</attr></ext><ext><name>ref</name><attr> name=Suicide10</attr></ext> There are a variety of risk factors, including male gender, depression, and a high [[intelligence quotient]].<ext><name>ref</name><attr> name=Suicide10</attr><inner>{{cite journal |author=Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P |title=Suicide in schizophrenia |journal=Expert Rev Neurother |volume=10 |issue=7 |pages=1153–64 |date=July 2010  |pmid=20586695 |doi=10.1586/ern.10.82 |url=}}</inner><close>&lt;/ref&gt;</close></ext>

[[Schizophrenia and smoking]] have shown a strong association in studies world-wide.<ext><name>ref</name><attr> name=&quot;de Leon&quot;</attr><inner>{{cite journal|pmid=15949648|year=2005|author=De Leon J, Diaz FJ|title=A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors|volume=76|issue=2-3|pages=135–57|doi=10.1016/j.schres.2005.02.010|journal=Schizophrenia research}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=&quot;Keltner&quot;</attr><inner>{{cite journal|doi=10.1111/j.1744-6163.2006.00085.x|title=Smoke, Smoke, Smoke That Cigarette|year=2006|author=Keltner NL, Grant JS|journal=Perspectives in Psychiatric Care|volume=42|pages=256–61|pmid=17107571|issue=4}}</inner><close>&lt;/ref&gt;</close></ext> Use of cigarettes is especially high in individuals diagnosed with schizophrenia, with estimates ranging from 80 to 90% being regular smokers, as compared to 20% of the general population.<ext><name>ref</name><attr> name=&quot;Keltner&quot;</attr></ext> Those who smoke tend to smoke heavily, and additionally smoke cigarettes with high nicotine content.<ext><name>ref</name><attr> name=DSM304</attr><inner>American Psychiatric Association. Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Pub. ISBN 978-0-89042-025-6. p. 304</inner><close>&lt;/ref&gt;</close></ext> Some evidence suggests that paranoid schizophrenia may have a better prospect than other types of schizophrenia for independent living and occupational functioning.<ext><name>ref</name><attr> name=DSM314</attr><inner>American Psychiatric Association. Task Force on DSM-IV. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Pub. ISBN 978-0-89042-025-6. p. 314</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="21">==Epidemiology==</h>
[[File:Schizophrenia world map - DALY - WHO2004.svg|thumb|[[Disability-adjusted life year]]s lost due to schizophrenia per 100,000&amp;nbsp;inhabitants in 2004.
<template lineStart="1"><title>Multicol</title></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#b3b3b3</value></part><part><name index="2"/><value>no data</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ffff65</value></part><part><name index="2"/><value>≤&amp;nbsp;185</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#fff200</value></part><part><name index="2"/><value>185–197</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ffdc00</value></part><part><name index="2"/><value>197–207</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ffc600</value></part><part><name index="2"/><value>207–218</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ffb000</value></part><part><name index="2"/><value>218–229</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff9a00</value></part><part><name index="2"/><value>229–240</value></part></template>
<template lineStart="1"><title>Multicol-break</title></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff8400</value></part><part><name index="2"/><value>240–251</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff6e00</value></part><part><name index="2"/><value>251–262</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff5800</value></part><part><name index="2"/><value>262–273</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff4200</value></part><part><name index="2"/><value>273–284</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#ff2c00</value></part><part><name index="2"/><value>284–295</value></part></template>
<template lineStart="1"><title>legend</title><part><name index="1"/><value>#cb0000</value></part><part><name index="2"/><value>≥&amp;nbsp;295</value></part></template>
<template lineStart="1"><title>Multicol-end</title></template>]]
<template lineStart="1"><title>Main</title><part><name index="1"/><value>Epidemiology of schizophrenia</value></part></template>

Schizophrenia affects around 0.3–0.7% of people at some point in their life,<ext><name>ref</name><attr> name=Lancet09</attr></ext> or 24&amp;nbsp;million people worldwide as of 2011.<ext><name>ref</name><attr/><inner>{{cite web |url=http://www.who.int/mental_health/management/schizophrenia/en/ |title=Schizophrenia |publisher=World Health Organization |year= 2011 |accessdate= 27 February 2011}}</inner><close>&lt;/ref&gt;</close></ext> It occurs 1.4&amp;nbsp;times more frequently in males than females and typically appears earlier in men<ext><name>ref</name><attr> name=BMJ07</attr></ext>—the peak ages of onset are 25 years for males and 27 years for females.<ext><name>ref</name><attr> name=Cascio</attr><inner>{{cite journal|author=Cascio MT, Cella M, Preti A, Meneghelli A, Cocchi A|title=Gender and duration of untreated psychosis: a systematic review and meta-analysis|journal=Early intervention in psychiatry|date=May 2012|volume=6|issue=2|pages=115–27|pmid=22380467|type= Review|doi=10.1111/j.1751-7893.2012.00351.x}}</inner><close>&lt;/ref&gt;</close></ext> [[Pediatric schizophrenia|Onset in childhood]] is much rarer,<ext><name>ref</name><attr> name=&quot;Kumra_et_al_2001&quot;</attr><inner>{{cite journal |author=Kumra S, Shaw M, Merka P, Nakayama E, Augustin R |year=2001 |title=Childhood-onset schizophrenia: research update |journal=Canadian Journal of Psychiatry |volume=46 | issue=10 |pages=923–30 |pmid=11816313}}</inner><close>&lt;/ref&gt;</close></ext> as is onset in middle- or old age.<ext><name>ref</name><attr/><inner>{{cite book| author = Hassett Anne, et al. (eds) | title = Psychosis in the Elderly | publisher = London: Taylor and Francis. |isbn=1-84184-394-6 | year = 2005 | page = 6 | url = http://books.google.com/?id=eLaMOJ9oj28C&amp;printsec=frontcover&amp;dq=Psychosis+in+the+Elderly }}</inner><close>&lt;/ref&gt;</close></ext> Despite the received wisdom that schizophrenia occurs at similar rates worldwide, its frequency varies across the world,<ext><name>ref</name><attr> name=DSM5pg101</attr></ext><ext><name>ref</name><attr> name=&quot;Jablensky_et_al_1992&quot;</attr><inner>{{cite journal |author=Jablensky A, Sartorius N, Ernberg G, et al. |year=1992 |title=Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study |journal=Psychological Medicine Monograph Supplement |volume=20 |pages=1–97 |pmid=1565705 |doi=10.1017/S0264180100000904}}</inner><close>&lt;/ref&gt;</close></ext> within countries,<ext><name>ref</name><attr> name=&quot;Kirkbride_et_al_2006&quot;</attr><inner>{{cite journal |author=Kirkbride JB, Fearon P, Morgan C, et al. |title=Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study |journal=Archives of General Psychiatry |volume=63 |issue=3 |pages=250–8 |date=March 2006  |pmid=16520429 |doi=10.1001/archpsyc.63.3.250}}</inner><close>&lt;/ref&gt;</close></ext> and at the local and neighborhood level.<ext><name>ref</name><attr> name=&quot;Kirkbride_et_al_2007&quot;</attr><inner>{{cite journal |author=Kirkbride JB, Fearon P, Morgan C, et al. |year=2007 |title=Neighbourhood variation in the incidence of psychotic disorders in Southeast London |journal=Social Psychiatry and Psychiatric Epidemiology |volume=42 | issue=6 |pages=438–45 |pmid=17473901 | doi = 10.1007/s00127-007-0193-0}}</inner><close>&lt;/ref&gt;</close></ext> It causes approximately 1% of worldwide [[disability adjusted life years]]<ext><name>ref</name><attr> name=&quot;BMJ07&quot;</attr></ext> and resulted in 20,000 deaths in 2010.<ext><name>ref</name><attr> name=Loz2012</attr><inner>{{cite journal |author=Lozano R, Naghavi M, Foreman K, et al. |title=Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 |journal=Lancet |volume=380 |issue=9859 |pages=2095–128 |date=December 2012  |pmid=23245604 |doi=10.1016/S0140-6736(12)61728-0 }}</inner><close>&lt;/ref&gt;</close></ext> The rate of schizophrenia varies up to threefold depending on how it is defined.<ext><name>ref</name><attr> name=Lancet09</attr></ext>

In 2000, the [[World Health Organization]] found the prevalence and incidence of schizophrenia to be roughly similar around the world, with age-standardized prevalence per 100,000 ranging from 343 in Africa to 544 in Japan and Oceania for men and from 378 in Africa to 527 in Southeastern Europe for women.<ext><name>ref</name><attr/><inner>{{cite web|title=Global burden of schizophrenia in the year 2000|url=http://www.who.int/healthinfo/statistics/bod_schizophrenia.pdf|publisher=[[World Health Organization]]|author=Ayuso-Mateos JL|accessdate=27 February 2013}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="22">==History==</h>
<template lineStart="1"><title>Main</title><part><name index="1"/><value>History of schizophrenia</value></part></template>
In the early 20th century, the psychiatrist [[Kurt Schneider]] listed the forms of psychotic symptoms that he thought distinguished schizophrenia from other psychotic disorders. These are called ''first-rank symptoms'' or [[Kurt Schneider#First-rank symptoms in schizophrenia|Schneider's first-rank symptoms]]. They include delusions of being controlled by an external force; the belief that thoughts are being inserted into or withdrawn from one's conscious mind; the belief that one's thoughts are being broadcast to other people; and hearing hallucinatory voices that comment on one's thoughts or actions or that have a conversation with other hallucinated voices.<ext><name>ref</name><attr> name=&quot;SchneiderClinicalPsychopathology&quot;</attr><inner>{{cite book|last1=Schneider |first1=K |authorlink1=Kurt Schneider |title=Clinical Psychopathology |url=http://books.google.com/?id=ofzOAAAAMAAJ |edition=5 |year=1959 |publisher=Grune &amp; Stratton |location=New York }}</inner><close>&lt;/ref&gt;</close></ext> Although they have significantly contributed to the current diagnostic criteria, the [[Sensitivity and specificity|specificity]] of first-rank symptoms has been questioned. A review of the diagnostic studies conducted between 1970 and 2005 found that they allow neither a reconfirmation nor a rejection of Schneider's claims, and suggested that first-rank symptoms should be de-emphasized in future revisions of diagnostic systems.<ext><name>ref</name><attr> name=&quot;pmid17562695&quot;</attr><inner>{{cite journal |author=Nordgaard J, Arnfred SM, Handest P, Parnas J |title=The diagnostic status of first-rank symptoms |journal=Schizophrenia Bulletin |volume=34 |issue=1 |pages=137–54 |date=January 2008  |pmid=17562695 |pmc=2632385 |doi=10.1093/schbul/sbm044}}</inner><close>&lt;/ref&gt;</close></ext>

The history of schizophrenia is complex and does not lend itself easily to a linear narrative.<ext><name>ref</name><attr/><inner>{{cite web| author==Yuhas, Daisy|title=Throughout History, Defining Schizophrenia Has Remained a Challenge|url=http://www.scientificamerican.com/article.cfm?id=throughout-history-defining-schizophrenia-has-remained-challenge|publisher=Scientific American Mind (March/April 2013)|accessdate=3 March 2013}}</inner><close>&lt;/ref&gt;</close></ext> Accounts of a schizophrenia-like [[syndrome]] are thought to be rare in historical records before the 19th century, although reports of irrational, unintelligible, or uncontrolled behavior were common. A detailed case report in 1797 concerning [[James Tilly Matthews]], and accounts by [[Phillipe Pinel]] published in 1809, are often regarded as the earliest cases of the illness in the medical and psychiatric literature.<ext><name>ref</name><attr> name=&quot;Heinrichs2003&quot;</attr><inner>{{cite journal |author=Heinrichs RW |title=Historical origins of schizophrenia: two early madmen and their illness |journal=Journal of the History of the Behavioral Sciences |volume=39 |issue=4 |pages=349–63 |year=2003 |pmid=14601041 |doi=10.1002/jhbs.10152}}</inner><close>&lt;/ref&gt;</close></ext> The Latinized term ''[[dementia praecox]]'' was first used by German alienist Heinrich Schule in 1886 and then in 1891 by [[Arnold Pick]] in a case report of a psychotic disorder (hebephrenia). In 1893 [[Emil Kraepelin]] borrowed the term from Schule and Pick and in 1899 introduced a broad new distinction in the [[classification of mental disorders]] between ''dementia praecox'' and mood disorder (termed manic depression and including both unipolar and bipolar depression).<ext><name>ref</name><attr/><inner>{{cite book|author=Noll, Richard|title=American madness: the rise and fall of dementia praecox|year=2011|publisher=Harvard University Press|location=Cambridge, MA|isbn=978-0-674-04739-6}}</inner><close>&lt;/ref&gt;</close></ext>  Kraepelin believed that ''dementia praecox'' was probably caused by a long-term, smouldering systemic or &quot;whole body&quot; disease process that affected many organs and peripheral nerves in the body but which affected the brain after puberty in a final decisive cascade.<ext><name>ref</name><attr/><inner>{{cite journal|author=Noll R|title=Whole body madness|journal=Psychiatric Times |year=2012 |volume=29|issue=12|pages=13–14|url=http://www.psychiatrictimes.com/blog/couchincrisis/content/article/10168/2104852}}</inner><close>&lt;/ref&gt;</close></ext>  His use of the term &quot;praecox&quot; distinguished it from other forms of dementia such as [[Alzheimer's disease]] which typically occur later in life.<ext><name>ref</name><attr> name=&quot;fn_49&quot;</attr><inner>{{cite book |author=Hansen RA, Atchison B |title=Conditions in occupational therapy: effect on occupational performance |publisher=Lippincott Williams &amp; Wilkins |location=Hagerstown, MD |year=2000 |isbn=0-683-30417-8}}</inner><close>&lt;/ref&gt;</close></ext> It is sometimes argued that the use of the term ''démence précoce'' in 1852 by the French physician Bénédict Morel constitutes the medical discovery of schizophrenia. However this account ignores the fact that there is little to connect Morel's descriptive use of the term and the independent development of the ''dementia praecox'' disease concept at the end of the nineteenth-century.<ext><name>ref</name><attr> name=&quot;Berriosetal2003&quot;</attr><inner>{{cite journal | author = Berrios G.E., Luque R, Villagran J | year = 2003 | title = Schizophrenia: a conceptual history | url = | journal = International Journal of Psychology and Psychological Therapy | volume = 3 | issue =2 | pages = 111–140 }}</inner><close>&lt;/ref&gt;</close></ext>

[[File:Chlorpromazine-3D-vdW.png|thumb|left|Molecule of [[chlorpromazine]] (trade name Thorazine), which revolutionized treatment of schizophrenia in the 1950s]]
The word ''schizophrenia''—which translates roughly as &quot;splitting of the mind&quot; and comes from the [[Ancient Greek|Greek]] roots ''schizein'' (σχίζειν, &quot;to split&quot;) and ''phrēn'', ''phren-'' (φρήν, φρεν-, &quot;mind&quot;)<ext><name>ref</name><attr/><inner>{{cite journal |author=Kuhn R |title=Eugen Bleuler's concepts of psychopathology |journal=History of Psychiatry|volume=15 |issue=3 |year=2004 |pages=361–6 |doi=10.1177/0957154X04044603 |pmid=15386868 |others=tr. Cahn CH}}</inner><close>&lt;/ref&gt;</close></ext>—was coined by [[Eugen Bleuler]] in 1908 and was intended to describe the separation of function between [[personality psychology|personality]], [[thought|thinking]], [[memory]], and [[perception]]. American and British interpretations of Beuler led to the claim that he described its main symptoms as 4 ''A'''s: flattened ''Affect'', ''Autism'', impaired ''Association'' of ideas and ''Ambivalence''.<ext><name>ref</name><attr> name=&quot;fn_78&quot;</attr><inner>{{cite journal |author=Stotz-Ingenlath G |title=Epistemological aspects of Eugen Bleuler's conception of schizophrenia in 1911 |journal=Medicine, Health Care and Philosophy |volume=3 |issue=2 |pages=153–9 |year=2000 |pmid=11079343|url=http://www.kluweronline.com/art.pdf?issn=1386-7423&amp;volume=3&amp;page=153|format=PDF |doi=10.1023/A:1009919309015}}</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr/><inner>{{cite journal|author=McNally K|title=Eugen Bleuler's &quot;Four A's&quot;|journal=History of Psychology|year=2009|volume=12|pages=43–59|doi=10.1037/a0015934|pmid=19831234|issue=2}}</inner><close>&lt;/ref&gt;</close></ext>  Bleuler realized that the illness was not a dementia, as some of his patients improved rather than deteriorated, and thus proposed the term schizophrenia instead. Treatment was revolutionized in the mid-1950s with the development and introduction of [[chlorpromazine]].<ext><name>ref</name><attr> name=&quot;Turner2007&quot;</attr><inner>{{cite journal | author=Turner T | title=Unlocking psychosis | journal=British Medical Journal | year=2007 | volume=334 | issue=suppl | pages=s7 | doi=10.1136/bmj.39034.609074.94 | pmid=17204765 }}</inner><close>&lt;/ref&gt;</close></ext>

In the early 1970s, the diagnostic criteria for schizophrenia were the subject of a number of controversies which eventually led to the [[operational definition|operational criteria]] used today. It became clear after the 1971 US-UK Diagnostic Study that schizophrenia was diagnosed to a far greater extent in America than in Europe.<ext><name>ref</name><attr> name=&quot;Wing1971&quot;</attr><inner>{{cite journal |author=Wing JK |title=International comparisons in the study of the functional psychoses |journal=British Medical Bulletin |volume=27 |issue=1 |pages=77–81 |date=January 1971  |pmid=4926366}}</inner><close>&lt;/ref&gt;</close></ext> This was partly due to looser diagnostic criteria in the US, which used the [[DSM-II]] manual, contrasting with Europe and its [[ICD-9]]. [[David Rosenhan|David Rosenhan's]] 1972 study, published in the journal ''[[Science (journal)|Science]]'' under the title &quot;[[Rosenhan experiment|On being sane in insane places]]&quot;, concluded that the diagnosis of schizophrenia in the US was often subjective and unreliable.<ext><name>ref</name><attr/><inner>{{cite journal |author=Rosenhan D |year=1973 |title=On being sane in insane places |journal=[[Science (journal)|Science]] |volume=179 |pages=250–8 |pmid=4683124| doi=10.1126/science.179.4070.250 |issue=4070}}</inner><close>&lt;/ref&gt;</close></ext> These were some of the factors leading to the revision not only of the diagnosis of schizophrenia, but the revision of the whole DSM manual, resulting in the publication of the [[DSM-III]] in 1980.<ext><name>ref</name><attr> name=&quot;Wilson1993&quot;</attr><inner>{{cite journal |author=Wilson M |title=DSM-III and the transformation of American psychiatry: a history |journal=[[American Journal of Psychiatry]] |volume=150 |issue=3 |pages=399–410 |date=March 1993  |pmid=8434655 }}</inner><close>&lt;/ref&gt;</close></ext>
The term schizophrenia is commonly misunderstood to mean that affected persons have a &quot;split personality&quot;. Although some people diagnosed with schizophrenia may hear voices and may experience the voices as distinct personalities, schizophrenia does not involve a person changing among distinct multiple personalities. The confusion arises in part due to the literal interpretation of Bleuler's term schizophrenia (Bleuler originally associated Schizophrenia with dissociation and included split personality in his category of Schizophrenia<ext><name>ref</name><attr/><inner>Stotz-Ingenlath G: Epistemological aspects of Eugen Bleuler’s conception of schizophrenia in 1911. ''Med Health Care Philos'' 2000; 3:153—159</inner><close>&lt;/ref&gt;</close></ext><ext><name>ref</name><attr> name=mhpsampd</attr><inner>Hayes, J. A., &amp; Mitchell, J. C. (1994). Mental health professionals' skepticism about multiple personality disorder. Professional Psychology: Research and Practice, 25, 410-415</inner><close>&lt;/ref&gt;</close></ext>). Dissociative identity disorder (having a &quot;split personality&quot;) was also often misdiagnosed as Schizophrenia based on the loose criteria in the DSM-II.<ext><name>ref</name><attr> name=mhpsampd</attr></ext><ext><name>ref</name><attr/><inner>Putnam, Frank W. (1989). Diagnosis and Treatment of Multiple Personality Disorder. New York: The Guilford Press. pp. 351. ISBN 0-89862-177-1</inner><close>&lt;/ref&gt;</close></ext> The first known misuse of the term to mean &quot;split personality&quot; was in an article by the poet [[T. S. Eliot]] in 1933.<ext><name>ref</name><attr> name=&quot;fn_3&quot;</attr><inner>{{cite book|author=Berrios, G. E.; Porter, Roy |title=A history of clinical psychiatry: the origin and history of psychiatric disorders |publisher=Athlone Press |location=London |year=1995 |isbn=0-485-24211-7}}</inner><close>&lt;/ref&gt;</close></ext> Other scholars have traced earlier roots.<ext><name>ref</name><attr/><inner>{{cite journal|author=McNally K|title=Schizophrenia as split personality/Jekyll and Hyde: the origins of the informal usage in the English language|journal=Journal of the history of the behavioral sciences|date=Winter 2007|volume=43|issue=1|pages=69–79|pmid=17205539|doi=10.1002/jhbs.20209}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="23">==Society and culture==</h>
<template lineStart="1"><title>See also</title><part><name index="1"/><value>List of people with schizophrenia</value></part><part><name index="2"/><value>Religion and schizophrenia</value></part></template>
[[File:Eugen bleuler.jpg|thumb|upright|The term schizophrenia was coined by [[Eugen Bleuler]].]]
In 2002 the term for schizophrenia in Japan was changed from ''Seishin-Bunretsu-Byō'' 精神分裂病 (mind-split-disease) to ''Tōgō-shitchō-shō'' 統合失調症 ([[integration disorder]]) to reduce stigma.<ext><name>ref</name><attr/><inner>{{cite journal |author=Kim Y, Berrios GE |title=Impact of the term schizophrenia on the culture of ideograph: the Japanese experience |journal=Schizophr Bull |volume=27 |issue=2 |pages=181–5 |year=2001 |pmid=11354585 |doi=10.1093/oxfordjournals.schbul.a006864}}</inner><close>&lt;/ref&gt;</close></ext> The new name was inspired by the [[biopsychosocial model]]; it increased the percentage of patients who were informed of the diagnosis from 37 to 70% over three years.<ext><name>ref</name><attr> name=&quot;Sato&quot;</attr><inner>{{cite journal |author=Sato M |year=2004 |title=Renaming schizophrenia: a Japanese perspective |journal=World Psychiatry |volume=5 | issue=1 |pages=53–55 |pmid=16757998 |pmc=1472254}}</inner><close>&lt;/ref&gt;</close></ext> A similar change was made in South Korea in 2012.<ext><name>ref</name><attr/><inner>{{cite journal|last=Lee|first=Yu Sang|author2=Kim, Jae-Jin |author3=Kwon, Jun Soo |title=Renaming schizophrenia in South Korea|journal=The Lancet|volume=382|issue=9893|pages=683–684|doi=10.1016/S0140-6736(13)61776-6}}</inner><close>&lt;/ref&gt;</close></ext>

In the United States, the cost of schizophrenia—including direct costs (outpatient, inpatient, drugs, and long-term care) and non-health care costs (law enforcement, reduced workplace productivity, and unemployment)—was estimated to be $62.7 billion in 2002.<ext><name>ref</name><attr/><inner>{{cite journal |author=Wu EQ |year=2005 |title=The economic burden of schizophrenia in the United States in 2002 |journal=J Clin Psychiatry |volume=66 | issue=9 |pages=1122–9|pmid=16187769 |doi=10.4088/jcp.v66n0906}}</inner><close>&lt;/ref&gt;</close></ext> The [[A Beautiful Mind (book)|book]] and [[A Beautiful Mind (film)|film]] ''A Beautiful Mind'' chronicles the life of [[John Forbes Nash]], a [[Nobel Prize]]-winning mathematician who was diagnosed with schizophrenia.

<h level="3" i="24">===Violence===</h>
Individuals with severe mental illness including schizophrenia are at a significantly greater risk of being victims of both violent and non-violent crime.<ext><name>ref</name><attr/><inner>{{cite journal |author=Maniglio R |title=Severe mental illness and criminal victimization: a systematic review |journal=Acta Psychiatr Scand |volume=119 |issue=3 |pages=180–91 |date=March 2009  |pmid=19016668 |doi=10.1111/j.1600-0447.2008.01300.x }}</inner><close>&lt;/ref&gt;</close></ext> Schizophrenia has been associated with a higher rate of violent acts, although this is primarily due to higher rates of [[Substance abuse|drug use]].<ext><name>ref</name><attr> name=Fazel</attr><inner>{{cite journal |author=Fazel S, Gulati G, Linsell L, Geddes JR, Grann M |title=Schizophrenia and violence: systematic review and meta-analysis |journal=PLoS Med. |volume=6 |issue=8 |pages=e1000120 |date=August 2009  |pmid=19668362 |pmc=2718581 |doi=10.1371/journal.pmed.1000120 }}</inner><close>&lt;/ref&gt;</close></ext> Rates of [[homicide]] linked to psychosis are similar to those linked to substance misuse, and parallel the overall rate in a region.<ext><name>ref</name><attr/><inner>{{cite journal |author=Large M, Smith G, Nielssen O |title=The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis |journal=Schizophr. Res. |volume=112 |issue=1-3 |pages=123–9 |date=July 2009  |pmid=19457644 |doi=10.1016/j.schres.2009.04.004 }}</inner><close>&lt;/ref&gt;</close></ext> What role schizophrenia has on violence independent of drug misuse is controversial, but certain aspects of individual histories or mental states may be factors.<ext><name>ref</name><attr/><inner>{{cite journal |author=Bo S, Abu-Akel A, Kongerslev M, Haahr UH, Simonsen E |title=Risk factors for violence among patients with schizophrenia |journal=Clin Psychol Rev |volume=31 |issue=5 |pages=711–26 |date=July 2011  |pmid=21497585 |doi=10.1016/j.cpr.2011.03.002 }}</inner><close>&lt;/ref&gt;</close></ext>

Media coverage relating to violent acts by individuals with schizophrenia reinforces public perception of an association between schizophrenia and violence.<ext><name>ref</name><attr> name= Fazel</attr></ext> In a large, representative sample from a 1999 study, 12.8% of Americans believed that individuals with schizophrenia were &quot;very likely&quot; to do something violent against others, and 48.1% said that they were &quot;somewhat likely&quot; to. Over 74% said that people with schizophrenia were either &quot;not very able&quot; or &quot;not able at all&quot; to make decisions concerning their treatment, and 70.2% said the same of money management decisions.<ext><name>ref</name><attr/><inner>{{cite journal |author=Pescosolido BA, Monahan J, Link BG, Stueve A, Kikuzawa S |title=The public's view of the competence, dangerousness, and need for legal coercion of persons with mental health problems |journal=American Journal of Public Health |volume=89 |issue=9 |pages=1339–45 |date=September 1999 |pmid=10474550 |pmc=1508769 |doi= 10.2105/AJPH.89.9.1339}}</inner><close>&lt;/ref&gt;</close></ext> The perception of individuals with psychosis as violent has more than doubled in prevalence since the 1950s, according to one meta-analysis.<ext><name>ref</name><attr/><inner>{{cite journal |author=Phelan JC, Link BG, Stueve A, Pescosolido BA|date=June 2000  |title=Public Conceptions of Mental Illness in 1950 and 1996: What Is Mental Illness and Is It to be Feared? |journal=Journal of Health and Social Behavior |volume=41 |issue=2 |pages=188–207 |doi=10.2307/2676305}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="25">==Research directions==</h>
<template lineStart="1"><title>See also</title><part><name index="1"/><value>Animal models of schizophrenia</value></part></template>
Research has found a tentative benefit in using [[minocycline]] to treat schizophrenia.<ext><name>ref</name><attr/><inner>{{cite journal|author=Dean OM, Data-Franco J, Giorlando F, Berk M|title=Minocycline: therapeutic potential in psychiatry|journal=CNS Drugs|date=1 May 2012|volume=26|issue=5|pages=391–401|pmid=22486246|doi=10.2165/11632000-000000000-00000}}</inner><close>&lt;/ref&gt;</close></ext> [[Nidotherapy]] or efforts to change the environment of people with schizophrenia to improve their ability to function, is also being studied; however, there is not enough evidence yet to make conclusions about its effectiveness.<ext><name>ref</name><attr/><inner>{{cite journal|author=Chamberlain IJ, Sampson S|title=Nidotherapy for people with schizophrenia|journal=Cochrane Database of Systematic Reviews|date=28 March 2013|volume=3|pages=CD009929|pmid=23543583|doi=10.1002/14651858.CD009929.pub2|editor1-last=Chamberlain|editor1-first=Ian J}}</inner><close>&lt;/ref&gt;</close></ext>

<h level="2" i="26">==References==</h>
<template lineStart="1"><title>Reflist</title><part><name index="1"/><value>2</value></part></template>

<h level="2" i="27">==External links==</h>
<template lineStart="1"><title>Sisterlinks</title><part><name>m</name><equals>=</equals><value>no</value></part><part><name>mw</name><equals>=</equals><value>no</value></part><part><name>voy</name><equals>=</equals><value>no </value></part><part><name>s</name><equals>=</equals><value>no</value></part><part><name>species </name><equals>=</equals><value> no </value></part><part><name>d</name><equals>=</equals><value>Q41112 </value></part><part><name>wikt</name><equals>=</equals><value>schizophrenia </value></part><part><name>v</name><equals>=</equals><value>no </value></part><part><name>b</name><equals>=</equals><value>no </value></part><part><name>q</name><equals>=</equals><value>no</value></part></template>
* <template><title>dmoz</title><part><name index="1"/><value>Health/Mental_Health/Disorders/Schizophrenia/</value></part></template>
<template lineStart="1"><title>Featured article</title></template>
<template lineStart="1"><title>Mental and behavioural disorders</title><part><name>selected </name><equals>=</equals><value> schizophrenia</value></part></template>

[[Category:Schizophrenia| ]]
[[Category:Psychosis]]
[[Category:Psychopathology]]
[[Category:Psychiatric diseases and disorders]]
[[Category:Psychiatric diagnosis]]

<template lineStart="1"><title>Link GA</title><part><name index="1"/><value>pl</value></part></template>
<template lineStart="1"><title>Link FA</title><part><name index="1"/><value>bn</value></part></template>
<template lineStart="1"><title>Spoken Wikipedia</title><part><name index="1"/><value>Schizophrenia 2.ogg</value></part></template>
<h level="2" i="28">==Simple English version==</h>
 [http://simple.wikipedia.org/wiki/Schizophrenia Read simpler version here. Click on loudspeaker (to the right on the simple English page) to listen.]</root>